Data and Safety Monitoring Plan (DSMP)



Comprehensive Cancer Center

Approved by NCI (08Dec2017) Revision #3 (06Dec2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

Page 1 of 77

Table of Contents

I.	Introduction	4
II.	Responsibilities of Cancer Center and Clinical Research Committees	5
III.	Data and Safety Monitoring Plan: Required Elements	8
IV.	Guidelines for Data and Safety Monitoring Implementation	8
V.	Implementation of Reporting Requirements	9
VI.	Monitoring Procedures	9
VII.	Data Quality Control	11
VIII.	Conflicts of Interest	13
IX.	Guidelines for Establishing and Operating a HDFCCC DSMB	14
APP	ENDICES	
А.	HDFCCC Clinical Trials Infrastructure	16
В.	Clinical Research Support Office	17
C.	DSM Organization	18
D.	List of Site Committees and Chairs	19
Е.	UCSF HDFCCC Data and Safety Monitoring Committee	20
Е.	PI Training Checklist	21
G.	Data and Safety Monitoring Reports: Subject Report	25
Н.	Data and Safety Monitoring Report: Regulatory Report	30
I.	DSMC Remediation Plan: Study Program Accrual Hold	36
Page 2 of 77	7 Approved by NCI (08Dec20 Provision #3 (06Dec20	,

J.		DSMC Remediation Plan: Study Program Accrual Reopening	37
K.		Model DSMP Templates for Investigators to Insert into Protocols	
	1.	DSMP for Phase 1 Dose Escalation Study (Single Site)	40
	2.	DSMP for Vaccine or Gene Therapy Study (Single Site)	44
	3.	DSMP for Phase 2 or 3 Study (Single Site)	48
	4.	DSMP for a Non-Therapeutic Study (Single Site)	52
	5.	DSMP for a Non-Therapeutic Study (Multicenter)	56
	6.	DSMP for a Phase 1 Dose Escalation Study (Multicenter)	61
	7.	DSMP for a Vaccine or Gene Therapy Study (Multicenter)	66
	8.	DSMP for a Phase 2 or 3 Study (Multicenter)	71
L.	Risk A	Assessment for Institutional Studies during DSMC Review	76

Page 3 of 77

Data and Safety Monitoring Plan UCSF Helen Diller Family Comprehensive Cancer Center

I. Introduction

UCSF Helen Diller Family Comprehensive Cancer Center Overview

The University of California at San Francisco Helen Diller Family Comprehensive Cancer Center (HDFCCC) is a National Cancer Institute (NCI) designated matrix center conducting a wide range of interdisciplinary research in the areas of laboratory, clinical, and population sciences. The HDFCCC is led by the Director of the Center, who is assisted by the Deputy Director. The remainder of senior leadership is comprised of Associate Directors of: Laboratory Research, Clinical Research, Population Science Research, Shared Resources, Education and Training and Administration.

Operational Definition of a Clinical Trial (NCI definition)

For purposes of the Data and Safety Monitoring Plan (DSMP), a clinical trial is operationally defined as a prospective study involving human subjects designed to answer specific questions about the effects or impact of particular biomedical or behavioral interventions. Clinical trials may be described as therapeutic or non-therapeutic interventions and can include drugs, treatments, devices, as well as behavioral or nutritional strategies. Participants in these trials are patients with a diagnosis of cancer, or, in the case of primary prevention studies, at risk for cancer. Behavioral clinical trials include interventions whose goals are to increase behaviors (e.g., cancer screening, physical activity, fruits and vegetable intake), eliminate or reduce behaviors (e.g., smoking, sun exposure) and/or improve coping and quality of life (e.g., among cancer survivors) and reduce the negative effect of treatment. These non-therapeutic interventional trials may pertain to cancer prevention, screening and early detection, symptom management, and survivorship.

In the area of molecular or imaging diagnostics, a study is a clinical trial if it uses the information from the diagnostic test in a manner that somehow affects medical decision-making for the study subjects. In this way, a key goal of the trial is to collect diagnostic information that has an impact on some aspect of outcomes or clinical assessments. By contrast, studies which do not use information from the diagnostic test in any manner that can affect the outcome of study subjects, but whose objective is only the gathering of data on the characteristics of a new diagnostic approach, are minimal risk trials and are not covered by this DSMP. The exception to this would be if performing the diagnostic test itself imposes some risk on study subjects.

Approved by NCI (08Dec2017) Revision #3 (06Dec2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

Page 4 of 77

Observational and epidemiological studies and those that do not test interventions are minimal risk trials and, thus, are not covered by this DSMP.

II. Responsibilities of the Component Units of the Helen Diller Family Comprehensive Cancer Center Clinical Trials Operations

• The Cancer Center Clinical Trials Oversight Committee (CCCROC) The CCCROC provides oversight to the Clinical Protocol and Data Management (CPDM) and the Protocol Review and Monitoring System (PRMS) (see Appendix A). The CPDM includes the Clinical Research Support Office (CRSO), and the Data and Safety Monitoring Committee (DSMC). The CRSO, PRMS, and the DSMC are independent units whose activity is overseen and integrated by the CCCROC. The CRSO, PRMS, and the DSMC are each led by an experienced senior faculty member and a seasoned operations staff manager. The faculty members of these units are responsible to the CCCROC, which is chaired by the Deputy Director and the staff managers of each of these units report to the Associate Director of Administration. The Deputy Director reports to the HDFCCC President and Director.

• Protocol Review and Monitoring System (PRMS)

The **PRMS**'s goal is to promote optimal review of the scientific merit, priorities and progress of all clinical research at the HDFCCC. PRMS functions are accomplished by rigorous review in a two-stage review process consisting of (1) disease-focused Site Committees and modality Site Committees, where initial scientific review, assessment of clinical protocol feasibility and projected accrual rates, and prioritization is undertaken; and (2) the Protocol Review Committee (PRC). The scope of the PRC review encompasses the scientific rationale, study design, expected accrual rates, adequacy of biostatistical input, feasibility of trial completion within an appropriate time period, prioritization in terms of scientific merit and patient availability, and ongoing review of scientific progress including reasonable study goals and accrual rates. The PRC is also charged with overall prioritization of all trials across the center. As described below, Site Committee review and approval is required before PRC review of a trial. Although input and review from Site Committees is a critical component of the PRMS process, the PRC has final PRMS authority regarding review, approval, monitoring and closure of trials. The PRC meets monthly.

• Site Committees

Each element of the clinical trials infrastructure (CRSO, DSMC, and PRMS) interfaces with clinical investigators through the **Site Committees**. HDFCCC clinical investigators are required to participate in a disease- or modality-specific Site Committee. There are 14 Site Committees; ten are disease specific and four are modality specific (Appendix D). All CCSG Programs with a major clinical component have designated Site Committees.

Page 5 of 77

In addition to protocol review, prioritization, and accrual and scientific relevance monitoring, Site Committees are responsible for the development, activation, and conduct of clinical trials. The DSMC conducts its audit functions by interfacing with Site Committees, and Site Committees monitor toxicities associated with its trials.

This is achieved through the CRSO, as described below. Site Committees meet at least monthly, and committees reviewing phase I or high risk trials are required to meet weekly.

• Clinical Research Support Office (CRSO)

The **CRSO** is composed of a Regulatory Affairs Unit and a Research Personnel Unit (Appendix B). The Regulatory Affairs Unit is responsible for protocol development of institutional trials, patient safety monitoring and reporting, federal compliance, protection of human subjects, and regulatory training for study team staff. The Research Personnel Unit is responsible for recruitment, hiring, onboarding, training, supervision, and performance management of all clinical research coordinators (CRCs). CRCs are responsible for the daily operations and execution of study protocols after activation, including source document collection, data entry, patient visit coordination and navigation, and monitoring visits. The Protocol Review and Monitoring System provides the scientific review and protocol feasibility, while the Data and Safety Monitoring Committee provides the monitoring and auditing oversight, for the trials conducted by the CRSO.

• UCSF Institutional Review Board (IRB)

The **IRB** is comprised of four committees (Laurel Heights Committee, Mt. Zion Committee, Parnassus Committee, and the Zuckerberg San Francisco General Hospital Committee) that share equal authority and responsibility. Each of the four panels meets twice a month, so that overall eight IRB meetings are held each month. Following PRC approval, the IRB reviews all HDFCCC protocols and determines final status (approval/disapproval) of each protocol.

• The Data and Safety Monitoring Committee (DSMC)

The **DSMC** is responsible for monitoring and auditing institutional trials for data validity, trial conduct, and serious adverse event (SAE) reporting. The risk assessment of the trial is determined by the phase of the trial, which in turn, designates the frequency of monitoring (see Appendix H). The HDFCCC Director appoints the faculty director of the DSMC. The DSMC Director together with the Deputy Director appoints other members of the DSMC. There DSMC members may serve in the committee indefinitely, as there is not a term limit. The DSMC meets every six weeks.

• Activities of the DSMC are overseen by CCCROC (Appendix A). The DSMC Director provides reports to the HDFCCC Director, Deputy Director, and

Page 6 of 77

CCCROC detailing DSM activities. Additionally, the minutes of each DSMC meeting are provided for review by the Deputy Director. When the DSMC identifies areas of concern, in addition to conferring with the Deputy Director, the DSMC Director notifies the Protocol Review Committee (PRC), CCCROC, and the UCSF IRB as warranted. The DSMC manager oversees the DSM Monitors and the Education and Training Coordinator (Appendix C).

• Phase I Institutional Trials

These trials are monitored (i.e., reviewed in real time) monthly, beginning one month after the enrollment of the first patient. In addition, all patients in each cohort are monitored prior to the approval to dose escalation. The DSMC chair reviews the DSMC monitoring report or obtains a verbal report from the DSMC monitor. Dose escalations are approved by the DSMC Chair or qualified alternate (i.e., Vice Chair) within two business days of the request. The DSMC monitoring report is then reviewed at the subsequent DSMC meeting. In the event that the committee does not concur with the DSMC Chair's decision, accrual is held while further investigation takes place.

• Phase II and III Institutional Trials

These trials are audited (i.e., reviewed retrospectively) twice per year, with all data from twenty percent of the enrolled patients reviewed by the DSMC Monitor.

- The regulatory files for all Institutional Trials are audited annually by the DSMC for regulatory compliance.
- DSMC monitoring reports are reviewed at the DSMC meeting following the • monitoring visit(s). The DSMC may request additional data or add recommendations. After the DSMC Chair approves the monitoring report, the report is then sent via e-mail to the PI and study team for follow-up. If serious non-compliance is identified during the monitoring visit, the DSMC will recommend to the DSMC Chair that a voluntary suspension on accrual be implemented while the PI and study team develop a corrective and preventative action (CAPA) plan. If there are serious or continuing compliance issues or an increased risk to subject safety in a study trial or study program, the DSMC may mandate a temporary enrollment suspension for a trial or a study program until a robust Corrective and Preventative Action (CAPA) plan is developed by the PI and study team. The DSMC Manager will notify the Industry Sponsor (i.e., Pharmaceutical Sponsor) and the NCI Program Director for NCI-CTEP trials of this suspension on trial activities. Once the suspension has been lifted by the DSMC, then the DSMC Manager will then notify the Industry Sponsor for

Approved by NCI (08Dec2017) Revision #3 (06Dec2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

Page 7 of 77

Industry-Sponsored trials and the NCI Program Director for NCI-CTEP trials of the lifting of this suspension on trial activities.

III. Data and Safety Monitoring Plan: Required Elements

All clinical trials conducted at the UCSF HDFCCC, except for minimal risk trials, must have a satisfactory DSMP, which is described in detail in the protocol. These plans will be reviewed by the PRC as part of the protocol approval process and are evaluated in relation to the potential risks and scale of the trial (see appendix H).

Elements of a Data and Safety Monitoring Plan (DSMP) include:

A. Delineation of responsibilities:

For all therapeutic and non-therapeutic interventional trials, the Principal Investigator (PI) is responsible for the supervision of the protocol conduct, patient consent procedure, patient enrollment, and collection of data, adverse event reporting, and ensuring that the protocol has current IRB approval. The Principal Investigator is also responsible for reporting of safety-related events to the HDFCCC DSMC, the UCSF IRB, the participating sites for multicenter studies (when UCSF is the Coordinating site), federal regulators (i.e., FDA) when the trial is conducted under an Investigational New Drug Application (IND, and the NCI CTEP (as applicable).

IV. Guidelines for Data and Safety Monitoring Implementation

- A. Principal Investigators will conduct review of data and patient safety at Site Committee meetings. Phase I trials will undergo weekly review and Phase II and III trials will undergo monthly review. Discussion and conclusions will be documented in the Site Committee meeting minutes. The discussion should include the following elements:
 - Screening, new patient enrollment, and accrual rates.
 - A per patient review of:
 - Significant toxicities as described in the protocol.
 - Grading of all significant toxicities.
 - Attribution of the relationship of the toxicity to the study drug.
 - Determination whether a toxicity was expected or unexpected.
 - Dose modifications per protocol.
 - Efficacy.
 - Rate of occurrence of adverse events as compared to the investigators brochure or package insert.

Page 8 of 77

B. Phase I-III therapeutic interventional clinical trials above minimal risk must have a DSMP that is directed toward the anticipated risks of the study and is commensurate with the level of risk to the participants. The DSMP must be included in the research proposal and must be approved by the PRC prior to opening the study.

V. Implementation of Reporting Requirements

A. Serious Adverse Event (SAE) Reporting

- The DSMC reviews all SAE Reports for all clinical trials (i.e., Industry-Sponsored, Institutional, and Cooperative Group) via an OnCore Report at the DSMC Meetings, which occur every 6 weeks.
- All deaths related to the Investigational Product or Investigational Device must be reported by the Principal Investigator (PI) to the DSMC chair within one business day.
- All SAEs, regardless of the relationship to the study, will be tracked in OnCore®, the UCSF HDFCCC data management tool.
- The Principal Investigator (or Study Chair) shall be responsible for notification of other participating institutions if the clinical trial involves multiple institutions and UCSF is the lead institution according to the protocol.

B. Study Progress

- The DSMC will use DSMC monitoring reports and protocol stopping rules to determine whether a study warrants closure.
- All external audits must be submitted to the DSMC, whether from Industry Sponsor audits or from NCI audits for review at DSMC meetings.
- The recommendations of the DSMC are forwarded to the Deputy Director of the HDFCCC. The Deputy Director of the HDFCCC and the DSMC Chair will provide communication to the IRB of any decisions for enrollment suspension within a study program for study non-compliance issues.

VI. Monitoring Procedure

The PRC determines the level of risk, which in turn, determines the monitoring/auditing frequency as outlined in Appendix H. The DSMC Monitor manages the logistics associated with the monitoring review sessions. Once the clinical trial is identified for monitoring, the DSMC Monitor arranges for a selection of cases to monitor from among the subjects registered in OnCore® based upon the guidelines in Appendix H. The Principal Investigator and Study Coordinators are notified via e-mail in advance of a scheduled monitoring session

Page 9 of 77

to arrange a mutually agreed upon time for the monitoring session. The investigator and research staff are responsible for gathering all of the materials needed for this review, including medical charts and other research records requested. For Multicenter trials, the participating sites are responsible for downloading the redacted source documents in the PC console of OnCore® for the DSMC Monitor to monitor/audit.

The DSMC Monitor reviews the regulatory files once per year when the trial is audited. The DSMC Monitor uses OnCore® and iRIS® to review the following in the trials reviewed:

- approval dates for protocols and amendments with no lapses in ongoing approvals.
- approved informed consent forms (ICF).
- approved study documents (e.g., patient diaries).
- SAEs and PV Reports to the IRB.
- Approved Protocol Eligibility Exceptions (PEE).
- IND Safety Reports.

Additionally, the DSMC reviews the following:

- The DSMC Monitor reviews the medical records as the source documents and verifies data entry in the electronic case report forms (OnCore®). The source documents are reviewed to ensure that there is adherence to the protocol and to identify if there are safety issues with the conduct of the study.
- Informed consent forms, HIPAA, and Bill of Rights documents properly obtained.
- Any required pre-study tests and procedures are obtained within the designated pre-treatment time interval.
- All eligibility criteria reviewed to ensure that the study patient is qualified for the trial.
- Adherence to treatment plan is documented, including Investigational Product (IP) orders, drug doses and dose reductions and/or treatment holds, if indicated.
- Accuracy, adequacy, completeness, and timeliness of data collection and submission.
- Appropriate and timely recording of adverse events (AEs) and reporting serious adverse events (SAEs) to the UCSF IRB.
- Review of possible dose limiting toxicities (DLTs).
- Adherence to patient follow-up requirements.

Following the completion of the monitoring session, the DSMC Monitor will complete the Monitoring Report (see Appendix G), which describes the findings of this monitoring

Page 10 of 77

visit. The study is given an overall evaluation by the DSMC Monitor (and approved by the DSMC Chair) of one of the following evaluations:

- Satisfactory (no follow-up required).
- Acceptable with follow-up items to be completed.
- Significant findings, with follow-up response to DSMC required.
- Unsatisfactory, halt enrollment of new subjects, corrective action plan required within 10 days to the DSMC. The DSMC Chair will notify the IRB regarding the results of this audit/monitoring visit

This evaluation is based upon the findings of the monitoring visit(s) and includes GCP compliance issues, subject safety issues, and protocol adherence issues. In rating the conduct of the study, the DSMC categorizes variances from the protocol as protocol violations. Major Protocol Violations are variances from the clinical trial-specified criteria or procedures that make the resulting data questionable and can affect patient safety. Examples of these would include failure to obtain informed consent prior to study related procedures or treatment or not reporting dose limiting toxicities. Minor Protocol Violations) are variances that do not affect the outcome or interpretation of the study or the safety of the study participants. Examples of these would include the investigator not grading the clinical significance of an abnormal lab or ECG or a patient occasionally forgetting to take the study drug during the study.

The significant findings of the DSMC Report are presented to the DSMC Chair and the DSMC Committee. The DSMC Committee votes on the following recommendations:

- **Full Approval**: Enrollment may continue; no outstanding questions regarding toxicity and/or accrual.
- **Conditional Approval**: Enrollment may continue conditionally upon a satisfactory response by the Principal Investigator to the DSMC concerning study conduct, toxicities, and/or accrual.
- **Suspension**: Enrollment is immediately suspended pending Principal Investigator response to DSMC concerns regarding serious protocol violations.
- **Closure**: Study is closed due to unacceptable study conduct and toxicities.

The DSMC Committee's decision is sent to the trial's Principal Investigator in writing, along with a copy of the monitoring report. If the Principal Investigator decides to appeal the DSMC decision, he/she may do so in writing. If the appeal is unsatisfactory, the Principal Investigator may appeal to the Deputy Director.

Page 11 of 77

VII. Data Quality Control

A. Pre-Industry Sponsored Audit and Pre-FDA Inspection DSMC Review

The DSMC will conduct a trial review prior to an Industry-Sponsored Quality Assurance audit, which is completed in preparation for a <u>potential</u> FDA Inspection. Additionally, the DSMC will conduct a pre-FDA Inspection Review in order to prepare the trial for a <u>scheduled</u> FDA Inspection. Both reviews will include a review of compliance for regulatory adherence, study patient review, and pharmacy review. For each DSMC review, the DSMC Monitor will review at a minimum:

- Informed consent.
- Eligibility.
- Randomization documentation (if applicable).
- Adherence to the protocol: protocol deviations/violations.
- Administration of drug, study drug orders, and dose adjustments due to adverse events per protocol.
- Recording of adverse events including CTCAE version 4.03 grading and attribution of each event
- Reporting of serious adverse events (SAEs)
- Evaluation of disease progression and tumor measurement (RECIST)
- Review of Regulatory files.
- Review of Pharmacy records.

The findings from these DSMC Reviews will be discussed with the PI and the study team and all issues will be resolved prior to either the Sponsor QA visit or the FDA Inspection. This may include the submission of reportable Protocol Violations with a Corrective and Preventative Action Plan (CAPA).

A. Education and Training for Study Staff

The Education and Training Coordinator (ETC) is a member of the DSMC and reports to the DSMC Manager. The ETC is responsible for the development of the onboarding and refresher-training curriculums for CRCs, PPMs, and the PIs (see Appendix F).

In addition to the UCSF required onboarding, including Collaborative Institutional Training Initiative (CITI) Good Clinical Practice (GCP) and Human Subjects Protection, and Health Insurance Portability and Accountability Act (HIPAA) training, the CRC onboarding series is offered every six weeks and is required for all new Cancer Center

> Approved by NCI (08Dec2017) Revision #3 (06Dec2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

Page 12 of 77

CRCs to attend. The training is led by Senior and Lead CRCs and organized by the Education and Training Coordinator.

All HDFCCC investigators are required to complete a comprehensive PI training program on the proper conduct of clinical research. New investigators are required to complete their training before being added as Investigator (i.e., listed on the FDA 1572 form) on any study in the HDFCCC. Investigators will be required to re-train every three years. The investigator-training program was implemented in October 2016. The PI training is conducted by the Education and Training Coordinator and the Manager of the Data Safety and Monitoring Committee.

B. Remediation Process

If there are significant safety issues within a study program (i.e., numerous Serious Noncompliance Determinations from the IRB or a significant loss of study staff) which put study patients at risk and affect the integrity of the data in the clinical trial(s), then the DSMC may place the study program on a mandatory enrollment suspension until these issues are resolved (Appendix I) The DSMC Manager and the DSMC Chair will communicate this decision to the Deputy Director and CCCROC, as well as notify the PI and the study team of this decision.

The formal decision from the DSMC will be communicated to the PI and the study team, as well as all HDFCCC Directors and Managers and the IRB of this decision. If this is an NCI-CTEP trial, then the NCI Program Director will be notified of this suspension on trial activities. If this is an Industry-Sponsored trial, then the Industry-Sponsor (i.e., Pharmaceutical company) will be notified of this suspension on trial activities. The study team will then complete the reporting form(s) to the IRB and update clinicaltrials.gov with this decision to suspend accrual.

The DSMC will work with the PI and the study team to ensure that all issues are resolved prior to the study team submitting a formal request to the DSMC to request that the mandatory suspension on enrollment be lifted.

After all issues have been satisfactorily resolved by the study team, the PI will request that the DSMC approve the removal of the accrual suspension (Appendix J). The DSMC will discuss this request at the next scheduled DSMC Meeting. After DSMC approval, the DSMC will communicate this approval to the CCCROC and the UCSF IRB and PRC, as well as the PI and study team, of this decision. Additionally, the NCI Program Director will be notified if this is a NCI-CTEP trial or the Industry-Sponsor will be notified if this is an Industry-Sponsored (i.e., Pharmaceutical trial) of this removal of accrual suspension. Once the study program accrual is resumed, the DSMC Manager and the

Page 13 of 77

DSMC Chair will meet with the study program Lead CRC and/or PPM on a regular basis (i.e., every other week) to review accrual, staffing, issues encountered with the trials within the study program. These meetings will continue for 6-12 months until confirmation that all issues are resolved within the study program.

If the DSMC determines that there are unacceptable toxicities as a result of the study conduct by the PI and the study team, then the DSMC can permanently suspend the trial. If this occurs, then CCCROC, the UCSF IRB, PRC, the PI and the study team will be notified, as well as the NCI Program Director if this is a NCI-CTEP trial and the Industry-Sponsor if this is an Industry-Sponsored (i.e., Pharmaceutical trial).

VIII. Conflict of Interest

The voting members of the DSMC (i.e., MDs) must step out from discussion during the DSMC meeting for any review of their trials in which they are the PI. If a monitoring visit report is from a trial in which the DSMC voting member is the PI, then the voting member must also recuse himself or herself from the discussion of this topic. Additionally, the DSMC Chair or Vice Chair cannot sign a Monitoring Visit Report (MVR) from a trial monitored/audited in the DSMC Chair or DSMC Vice Chair's Site Committee.

IX. Guidelines for Establishing and Operating a UCSF HDFCCC DSMB

1. Membership

- a. The HDFCCC DSMC Monitors will perform monitoring activities.
- b. Voting members of the DSMB will be the same voting members of the DSMC. Members should view themselves as representing the interest of patients and not that of the institution.

2. Meeting Procedures

- a. Frequency
 - i. DSMB reports will be reviewed at the DSMC Meetings every six weeks.
- b. Elements for Review
 - i. A written summary of status, toxicity and outcomes of the clinical trial will be prepared by the study coordinator and reviewed by the principal

Page 14 of 77

investigator and clinical trial statistician. The summary will be submitted to DSMB members allowing sufficient review time prior to meeting.

ii. This summary will also address specific toxicity concerns as well as concerns about the conduct of the trial. It may contain recommendations for consideration by the DSMB concerning whether to close the trial, report the results, or continue accrual or follow-up.

3. Recommendations

- a. It is the responsibility of the PI, the clinical trial statistician(s), and individual DSMB members to ensure that the DSMB is kept apprised of non-confidential results from other related studies that become available, and any programmatic concerns related to the clinical trial being monitored. It is the responsibility of the DSMB to determine the extent to which this information is relevant to its decisions related to the specific trial.
- b. DSMB recommendations will be given to the PI and Sponsor. The DSMB must provide an adequate rationale for recommendations made to change the trial for other than safety or efficacy reasons.
- c. The PI is responsible for implementing the change recommended by the DSMB as expeditiously as possible.
- d. If the PI does not agree with the DSMB recommendation, the sponsor must be informed of the reason for disagreement.
- e. The sponsor, DSMB Chair, and PI will be responsible for reaching a mutually acceptable decision about the study.

4. Release of Outcome Data

- a. In general, outcome data should not be made available to individuals outside of the DSMB until accrual has been completed and all patients have completed study treatment
- b. The DSMB may approve the release of outcome data on a confidential basis to the PI for planning the preparation of manuscripts and/or to a small number of others for future trial planning purposes.
- c. Any release of outcome data prior to the DSMB recommendation for general dissemination of results must be reviewed and approved by the DSMB.

Page 15 of 77

5. Confidentiality

- a. No communication, either written or verbal, of the deliberations or recommendations of the DSMB will be made outside of the DSMB.
- b. Outcome results are strictly confidential and must not be divulged to any nonmember until the recommendations to release the results are accepted and implemented.


6. Conflict of Interest

- a. DSMB members are subject to the UCSF policies regarding standards of conduct.
- b. Individuals invited to serve on the DSMB (voting or non-voting) will disclose any potential conflicts of interest, whether real or perceived, to the PI and the appropriate institutional officials, in accordance with the UCSF Conflict of Interest Policies. Conflict of interest can include professional interest, proprietary interest, and miscellaneous interest as described in 45 CFR Part 94.
- c. Decisions concerning whether individuals with potential conflicts of interest or the appearance of conflicts of interest may participate in the DSMB will be made in accordance with the UCSF Conflict of Interest Policies.
- d. Potential conflicts, which develop during a member's tenure on a DSMB, must also be disclosed and addressed in accordance with the UCSF Policies.

Approved by NCI (08Dec2017) Revision #3 (06Dec2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

Page 16 of 77


<u>Appendix A.</u> HDFCCC Clinical Trials Infrastructure: CCCROC coordinates the activities of the three units, each of which have a Faculty Director and a Staff Manager.



Approved by NCI (08Dec2017) Revision #3 (06Dec2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)


Page 17 of 77

Appendix B. Clinical Research Support Office: The two units of the CRSO, their staff directors, and personnel



Page 18 of 77

Appendix C: DSM Organization: The two units of the DSM and their staff manager and personnel.



Page 19 of 77

Appendix D. UCSF HDFCCC Site Committees

Site Committee

Chair

Breast Oncology Cancer Immunotherapeutics Cutaneous Oncology Developmental Therapeutics Gastrointestinal Oncology Genitourinary Oncology Gynecologic Oncology Hematopoietic Oncology (Adult) Neurologic Oncology Oral, Head & Neck Oncology Pediatric Oncology Radiation Oncology Supportive Care Thoracic Oncology John Park, MD Peter Sayre, MD Katy Tsai, MD Pamela Munster, MD Andrew Ko, MD Charles Ryan, MD Lee-May Chen, MD Thomas Martin, MD Nicholas Butowski, MD Alain Algazi, MD Annu Banerjee, MD Mary Feng, MD Chris Miaskowski RN, PhD Matthew Gubens, MD

Page 20 of 77

Appendix E. UCSF HDFCCC Data and Safety Monitoring Committee

Thierry Jahan, MD	Chair and Thoracic Oncology
Andrew Ko, MD	Vice Chair and Gastrointestinal Oncology
Rahul Aggarwal, MD	Vice Chair and Genitourinary Oncology
Jennie Taylor, MD	Neurologic Oncology
Kristin Shimano, MD	Pediatric Oncology
Michelle Melisko, MD	Breast Oncology
Weiyun Ai, MD	Hematologic Oncology
Steve Braunstein, MD	Radiation Oncology
Joan Hilton, PhD	Biostatistics Core
Maha Kadafour, PharmD	Investigational Drug Service

Data and Safety Monitors/Education and Training Coordinator:

John F. McAdams, MS, CCRP Bernadette Paolini, RN, CCRC Maureen Lance, RN, CCRC Fred Fishman, BS, CCRP Marvin Bolanos, BS, CCRP Amy Li, MPA Manager DSM DSM Monitor DSM Monitor DSM Monitor Education and Training Coordinator

Page 21 of 77

Appendix F: PI Training Checklists

Page 22 of 77

			1 1 1		1 1		
	UCSF Helen Diller Family Comprehe	nsive Cancer Center	UCSF ITR PI O	NBOARDI	NG CHECKL	IST	
	Employee Name:	Start Date:					
	New Hire Onboarding Requireme	ents					
	Training Topic		Completion Date	PI Initial	ETC/DSMC Manager	Initial	
	Introduction to UCSF HDFCCC & ITR						
	Department research staff & roles Introduction to UCSF clinical research data	systems				_	
	PI responsibilities for clinical trials						
	Protocol Review and Development						
	 Trial activation process (sit o CRC effort 	e committee, PRC)					
	 Sign off on final budget, ca 	lendar, and MCA					
	o IIT/IST o MCT						
	o Pharmacy orders						
	o 1572, DOA o SIV						
	 Cooperative group trials 						
	PI responsibilities for clinical trials						
	 After study activation Consent process 						
	o Screening window						
	 Eligibility criteria Enrollment 						
	PI responsibilities for clinical trials						
	Treatment phase Review patient order:						
	 Review patient orders Review, attribute, and sign 	labs					
	 Review, attribute, and sign 						
	 Assess and grade AE Report SAEs within 24 hou 	rs					
	 One on one time with CRC 						
here to search · ▼ Insert Page Layout Refere <u> </u>		ITR PI ONBOARDING CHECKLIST	Mail - John McAd		UCSF HDFCCC D	and the second se	2 3 ≡ 100% (− 30_ ^ // // d×
here to search	UCSF	Contraction of the second		a state sta	UCSF HDFCCC D	and the second se	30_ ^ <i>(ii</i> ; d×
here to search	UCSF	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Mailings Review View UCSF UCSF Helen Diller Family Comprehe	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Mailings Review View UCSF UCSF Helen Diller Family Comprehe O Meet with industry monitor Pt responsibilities for clinical triais	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Mailings Review View UCSF Helen Diller Family Comprehe • Meet with industry monito PI responsibilities for clinical trails • Financial information	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Mailings Review View UCSF Helen Diller Family Comprehe O Meet with industry monito P responsibilities for clinical trials O Financial information O Post avard analyst O Monitor balance sheets	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Mailings Review View UCSF Helen Diller Family Comprehe O Meet with industry monitor PI responsibilities for clinical trials • Financial information • Post award analyst • Monitor balance sheets • Review and sign of for stu	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Malings Review View UCSF Helen Diller Family Comprehe Meet with industry monito Pi responsibilities for clinical trials Pi financial information Pi Monitor balance sheets Nomitor balance sheets Regulatory & supervision	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Mailings Review View UCSF Helen Diller Family Comprehe O Meet with industry monit PI responsibilities for clinical trials O Meet with industry monit PI responsibilities for clinical trials O Monitor balance sheets O Monitor balance sheets O Review and analyst PI responsibilities for clinical trials O Review and analyst O Regulatory & supervision O Attend site committee	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Mailings Review View UCSF Helen Diller Family Comprehe O Meet with industry monitor Presponsibilities for clinical trials Presponsibilities for clinical trials O Monitor balance sheets O M	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Mailings Review View UCSF Helen Diller Family Comprehe	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Mailings Review View UCSF Helen Diller Family Comprehe O Meet with industry monitor Presponsibilities for clinical trials Presponsibilities for clinical trials O Monitor balance sheets O M	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Tes Malings Review View UCSF Helen Diller Family Comprehe Presponsibilities for clinical trials Presponsibilities for clinical trials Presponsibilities for clinical trials Review and sign off on stu Presponsibilities for clinical trials Regulatory & supervision Presponsibilities for clinical trials Regulatory & supervision Presponsibilities for clinical trials Regulatory & supervision Presponsibilities for clinical trials Review obdy/1572 logs Review UDdy/1572 logs Attend multiste teleconfe Respond tall emails in al	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF New Malings Review View	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF New Malings Review View	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Malinga Review View UCSF Helen Diller Family Comprehe Meter with industry monitor Presponsibilities for clinical trials Presponsibilities for clinical trials Presponsibilities for clinical trials Review and sign off on stu Presponsibilities for clinical trials Regulatory & supervision Presponsibilities for clinical trials Regulatory & supervision Presponsibilities for clinical trials Regulatory & supervision Presponsibilities for clinical trials Review DGA/1572 logs Attend multisite teleconfe Review DGA/1572 logs Attend multisite teleconfe Regond to all emails in an Audit vs. Insgention How to prepare Robes & responsibilities SoSMC role SoSMC role	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF New Malings Review View	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Mailings Review View Control of the second	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Malinga Review View UCSF Helen Diller Family Comprehe Meter with industry monitor Presponsibilities for clinical trials Monitor balance sheets Review and sign off on stur Presponsibilities for clinical trials Review DGA/1572 logs Attend multisite teleconfe Review DGA/1572 logs Attend multisite teleconfe Review DGA/1572 logs Attend tws. Inspection Review DGA/1572 logs Attend tws. Inspection Review DGA/1572 logs Attend tws. Inspection Biot treatment of study staff career goa Understand study staff career goa	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCSF Mailings Review View Control of the second	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm	nercial use	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCS Name of the second	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm UCSF ITR PI O	NBOARDI	NG CHECKL	S	30_ ^ <i>(ii</i> ; d×
here to search	UCS Name of the second	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm UCSF ITR PI O	NBOARDI	· · · · · · · 8 · · · · ·	S	30_ ^ <i>(ii</i> ; d×
here to search	UCS Name of the second	ITR PI ONBOARDING CHECKLIST	- Microsoft Word non-comm UCSF ITR PI O	NBOARDI	NG CHECKL	S	30_ ^ <i>(ii</i> ; d×

Page 23 of 77

UCSF Heler	n Diller Family Comprehensive Cancer Center	LICKE	DITDAD	
		UCSF II R	PITRAIN	VING CHECKLIST
Principal PI	Name:	Start Date:		
Established	d PI Training Requirements			
	Training Topic	Completion Date	PI Initial	ETC/DSMC Manager Initial
	to UCSF HDFCCC ITR ew and Monitoring System/ Protocol Review Committee			
Data and Safe	ety Monitoring Committee			
Department r Safet	research staff & roles			
	icol Development Team			
Cover	rage Analyst & Budget			
	arch team staff ities for clinical trials			
	col Review and Development Stage			
0	Trial activation process (site committee, PRC)			
	 CRC effort Sign off on final budget, calendar, and MCA 			
0	IIT/IST			
	MCT			
	Pharmacy orders 1572, DOA			
0	SIV			
	Cooperative group trials ities for clinical trials			
	study activation			
0	Consent process			
	 Consenting non-English speaking subjects Telephone consent 			
	Screening window			
	Eligibility criteria Enrollment			
	ties for clinical trials			
Mailings Review	UCSF ITR ESTABLISHED PI TRAINING CHEC	Mail - John.McAd		UCSF HDFCCC DS
	UCSF ITR ESTABLISHED PI TRAINING CHEO View			VUCSF HDFCCC DS
	UCSF ITR ESTABLISHED PI TRAINING CHE	CKLIST - Microsoft Word non	-commercial use	VING CHECKLIST
UCSF Heler	UCSF ITR ESTABLISHED PI TRAINING CHE View 2	CKLIST - Microsoft Word non	-commercial use	7
UCSF Heler • Treati	UCSF ITR ESTABLISHED PI TRAINING CHER View 2 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	CKLIST - Microsoft Word non	-commercial use	7
UCSF Haler	UCSF ITR ESTABLISHED PI TRAINING CHER View Diller Family Comprehensive Cancer Center ment phase Review patient orders Review, attribute, and sign labs	CKLIST - Microsoft Word non	-commercial use	7
UCSF Heler	UCSF ITR ESTABLISHED PT TRAINING CHER View 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	CKLIST - Microsoft Word non	-commercial use	7
• Treat	UCSF ITR ESTABLISHED PT TRAINING CHER View 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	CKLIST - Microsoft Word non	-commercial use	7
UCSF Heler	UCSF ITR ESTABLISHED PI TRAINING CHER View 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	CKLIST - Microsoft Word non	-commercial use	7
USF Heler • Treat • • • • • • • • • • • • •	UCSF ITR ESTABLISHED PT TRAINING CHER View 2	CKLIST - Microsoft Word non	-commercial use	7
• Treat • Treat • • • • • • • • • • • • • • • • • • •	UCSF ITR ESTABLISHED PT TRAINING CHER Verv 1 Diller Family Comprehensive Cancer Center ment plase 1 Review patient orders 1 Review, attribute, and sign labs 1 Review, attribute, and sign labs 1 Review, attribute, and sign labs 1 Review, attribute, and sign scans 1 Assess and grade AE 1 Report SAS: within 24 hours 1 One on one time with CRCs 1 Meet with industry monitors ties for clinical trials cali Information	CKLIST - Microsoft Word non	-commercial use	7
UQSF Heler • Treat • • • • • • • • • • • • • • • • • • •	UCSF ITR ESTABLISHED PT TRAINING CHER View 2	CKLIST - Microsoft Word non	-commercial use	7
UQSF Heler • Treat • Treat • O • O • O • O • O • O • O • O	UCSF ITR ESTABUSHED PT TRAINING CHER View 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	CKLIST - Microsoft Word non	-commercial use	7
UQSE Heler • Treati • O • O • O • O • O • O • O • O	UCSF ITR ESTABLISHED PI TRAINING CHER View Diller Family Comprehensive Cancer Center ment phase Review, attribute, and sign labs Review, attribute, and sign scans Review, attribute, and sign scans Review, attribute, and sign scans Review attribute, and sign scans Review attribute, and sign scans Period Satis within 24 hours One on one time with RCs Needow attributes Post award analyst Neonitor balance sheets Review and sign off on study charges Re	CKLIST - Microsoft Word non	-commercial use	7
UQSE Heler • Treat • Treat • O • O • O • O • O • Finan • Finan • Finan • Finan • O • O • O • O • O • O • O • O	UCSF ITR ESTABUSHED PT TRAINING CHER View 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	CKLIST - Microsoft Word non	-commercial use	7
UQSE Heler • Treat • Treat • O • O • O • O • O • O • O • O	UCSF ITR ESTABLISHED PT TRAINING CHER View	CKLIST - Microsoft Word non	-commercial use	7
VOSF Heler	UCSF ITR ESTABLISHED PT TRAINING CHER View 2	CKLIST - Microsoft Word non	-commercial use	7
UQSE Heler • Treat • • • • • • • • • • • • •	UCSF ITR ESTABLISHED PT TRAINING CHER View	CKLIST - Microsoft Word non	-commercial use	7
UCEF Heler • Treat • O • O • O • O • O • O • O • O	UCSF ITR ESTABLISHED PT TRAINING CHEE View Comparison of the second se	CKLIST - Microsoft Word non	-commercial use	7
UCSE Heler • Treati • O • O • O • O • O • O • O • O	UCSF ITR ESTABLISHED PT TRAINING CHER View	CKLIST - Microsoft Word non	-commercial use	7
UCSE Heler • Treati • O • O • O • O • O • O • O • O	UCSF ITR ESTABLISHED PT TRAINING CHER Vere 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	CKLIST - Microsoft Word non	-commercial use	7
UQSE Heler • Treat • Treat • O • O • O • O • O • O • O • O	UCSF ITR ESTABLISHED PT TRAINING CHER Vere 1 Diller Family Comprehensive Cancer Center ment phase 1 Diller Family Comprehensive Cancer Center ment phase 1 Review, attribute, and sign labs 1 Review (Table 1 Review) 1 Review Indiance sheets 1 Review and sign off on study charges 1 Review intrails 1 Review Intails 1 Review Intails 1 Review Intails 1 Review Intails 1 Review Internal/setternal safety reports 1 Review Internal/setternal safety reports 1 Review Internal/setternal safety reports 1 Review Idemails telesconference 1 Respond to all emails in a timely manner 2 Compassionate Use/Espanded Access 1 Review Idemails	CKLIST - Microsoft Word non	-commercial use	7
USE Heler • Treat • O • O • O • O • O • O • O • O	UCSF ITR ESTABLISHED PT TRAINING CHEE View Comparison of the second s	CKLIST - Microsoft Word non	-commercial use	7
USE Heler • Treat • Treat • O • O • O • O • O • Finan • O • Finan • O • O • O • O • O • O • O • O	UCSF ITR ESTABLISHED PT TRAINING CHEE View Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Co	CKLIST - Microsoft Word non	-commercial use	7
UCSE Heler	UCSF ITR ESTABUSHED PT TRAINING CHEE View	CKLIST - Microsoft Word non	-commercial use	7
UQSE Heler • Treat • Treat • O • O • PI responsibili • Regul • O • O • O • O • O • O • O • O	UCSF ITR ESTABLISHED PT TRAINING CHEE View Composition of the second o	CKLIST - Microsoft Word non	-commercial use	7
UQSE Heler • Treat • Treat • O • O • PI responsibili • Regul • O • O • O • O • O • O • O • O	UCSF ITR ESTABUSHED PT TRAINING CHEE View	CKLIST - Microsoft Word non	-commercial use	7
UQSE Heler • Treat • Treat • O • O • PI responsibili • Regul • O • O • O • O • O • O • O • O	UCSF ITR ESTABLISHED PT TRAINING CHEE View Composition of the second o	CKLIST - Microsoft Word non	-commercial use	7

Page 24 of 77

👿 🖗 - 🙂 🍠 - 🖛	UCS	FITR ESTABLISHED PI TRAINING CHECKLIST - Mic	crosoft Word non-commercial use		- 🛛 ×
File Home Insert Page Layout References Ma	ailings Review View				∞ 🕜
L	<u> </u>		· · · · · · · · · · · · · · · · · · ·		<u>ت</u>
	UCSF Helen Diller Family Comp	rehensive Cancer Center U	CSF ITR PI TRAINING CHE	CKLIST	Â
	Faculty Signature & Date	Education & Training Coordinator S	-		
	Faculty Signature & Date	Education & Training Coordinator S	Ignature & Date DSMC Manager Signature & I	Jate	
L					
				3	•
Page: 3 of 3 Words: 304 🕉					■ 100%
Type here to search	4 🖸 🤤 🚍	🔒 🖸 🚳 🛃 🌏 Mail - Jot	nn.McAd 🌀 😓 < 🗰 UCSF HI	And a second	

Page 25 of 77

Appendix G. Data and Safety Monitoring Reports: Subject Report

⊟ 5+	Q ÷	DS	SMC Subject	Monitoring	Template (v 019	Sep2016).doc [Compatibilit	y Mode] -	Word	Table	Tools					ħ	- 8 ×
File	Home	Insert	Design	Layout	References	Mailings	Review	View	ACROBAT	Design	Layout				M	Adams, John	A₁ Share
						110	QE Holon I	Dillor Ea	mily Compre	honoivo Ca	noor Conto	15					^
						00		Data Saf	fety Monitori	ing Report	iller Genile	71					
					+‡+			5	Subject Revi	ew							
					Study Title	2											
					CC #:					UCSF IRB UCSF IRB		Date:					
					Research G	roup:											
					Principal In	vestigator:											
					CRC:												
					Auditor:					Site Visit D	ate:						
					Current stu	dy status:				Total accrual to date:	Total nun of subject reviewed						
												- I					
					Study Man		reas of Re	view			Asse	essments	- 1				
						ent process is	s implement	ted per U	CSF IRB	a) 🔲	Yes 🔲 No	0	-				
					application					b) 🔲	Yes 🔲 No	•					
					protocol.	y nas eligibili	ity checklis	t that relie	ects the currer		Yes 🔲 No						
									nt was found.		Yes No						
						quality of pro					Yes 🛄No						
						s) were remov quality of data				f) 🔲	Yes 🔲 No)					
						y: current Co		actory (C.	1103).		Yes 🔲 No	N/A					
					DSM	MC approved	dose escala		ast cohort.		Yes 🔲 No						
					DL	Is were ident:	ified in this	cohort.									
					Toxicity do	ocumentation	1 and mana	agement									
					a) Subje	ects were dos	ed correctly			a) 🔲	l'es 🔲No	N/A					
					b) Dose	modification	s per protoc	:01.		b) 🔲	es 🔲 No	N/A					
					Comments	regarding s	tudy mana	gement:									
					The Conse	nt Process:											
												D 1	1				
					CC#: Program:						Repor	Page 1 rt date:					
Dens 1 of 5	985 wor	ds 🕮			Version 7.0;	01Sep2016					Subject	Monitoring Form					+ 89%
Page 1 of 5	10W C06	us ц⊿			-								_	90	EØ		+ 89%

Page 26 of 77

⊟ 5-	Q ÷	DS	MC Subject	Monitoring	toring Template (v 01Sep2016).doc [Compatibility Mode] - Word Table Tools									æ	- @ ×
File	Home	Insert	Design	Layout	References	Mailings	Review	View	ACROBAT	Design	Layout			McAdams, John	₽ Share
						UC		Data Saf	nily Compreh ety Monitorin Subject Revie	ng Report	ncer Cente	r]		٠
					Subject Re	views]		
					Subject initi			S	ubject ID #				-		
					with all requ b) Subject ii c) Were all d) Subject e signed off. e) Treatmen f) All assess g) AEs and documents. h) Were new Policy? i) CTMS da j) Did any P	onsented with uired signature s entered into screening and digibility con at per protoco sments comple SAEs entered w risks commenta: Are querie Protocol Viola	n correct IC res the CTMS i pretreatm firmed with 1 confirmed eted per pr i in CTMS unicated w es in OnCo ations or Co	F version with trea ent proceed a supporti- l. otocol. and confi- ith subject re? onsent Inco	rrent Status: by MD or nur tment status up tures done corr ng documentat rrmed by source ts as per Safety idents occur? I idents occur? I	o to date. rectly? ion and e y Reporting if yes:	f) ☐ Ye g) ☐ Y h) ☐ Ye i) ☐ Ye j) ☐ Ye	s No s No s No es No es No es No s No s No s No s No s No			
					Subject initi Monitored f a) Subject c with all requ b) Subject i c) Were all d) Subject e signed off.	uired signatur s entered into screening and ligibility con	ect ID #Subject a correct IC res the CTMS d pretreatm	s Current F version with trea	Status: by MD or nur tment status up tures done corn ag documentat	to date. rectly?	Repor	es No es No es No °age 2 t date:			
Page 2 of 5	Version 7.0; 01Sep2016									Subject 1	Monitoring Form	1	E 6	+ 89%	
	6		O		ل الم	L 0 <u>-</u>	w					• <u> </u>	ං 👅 🖏 න	o 🛯 🛬 💿 🖪 🕕 🗊	2:07 PM

Revision #3 (12Nov2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

금				Monitoring	Template (v 019	Sep2016).doc [Compatibilit	y Mode] -	Word						t	1 – D
File	Home	Insert	Design	Layout	References	Mailings	Review	View	ACROBAT	Design	Layout				McAdams, J	ohn A St
						UC		Data Saf	nily Compreh ety Monitorin Subject Review	g Report	icer Cente	r				
					 f) All assess g) AEs and documents. h) Were new Reporting F i) CTMS da j) Did any F 	SAEs entered w risks were o Policy? ata: Are queri Protocol Viola PV /Consent	leted per pr d in CTMS communica es in OnCo ations or Co	l. otocol, ind and confi ted with s re? msent Inc	cluding CT/MR rmed by source ubjects as per S idents occur? If ted per UCSF I	I. Safety f yes:	f) Yo g) Y h) Yo i) Y j) Y	es No es No es No es No es No es No es No es No	□ N/A			
					-	regarding s	ubject revi	ew:		1	~					
					Monitored :	ials Subj from to consented wit	Subjec		it Status: by MD or nurs	sing staff	a) 🔲 Y	es 🔲 No				
					 b) Subject i c) Were all d) Subject e signed off. 	screening and eligibility con	the CTMS d pretreatm firmed with	ent proced 1 supporti	tment status up lures done corro ng documentati	ectly?	b)	s 🔲 No				
					f) All assess g) AEs and documents.	SAEs entered	leted per pr d in CTMS	otocol, ind and confi	cluding CT/MR rmed by source ubjects as per S		e)	es 🔲 No				
					i) CTMS da j) Did any F	Policy? ata: Are queri Protocol Viola PV /Consent	es in OnCo ations or Co	re? msent Inc	idents occur? If ted per UCSF I	fyes:	i) 🔲 Y	es No es No es No es No es No	N/A			
					Comments CC#:	regarding s	ubject revi	ew:				Page 3 t date:				
					Program:											
	985 word				Program: Version 7.0;	01Sep2016						Monitoring	Form	88		+

Page 28 of 77

₽ 5-	Q ÷	DS	MC Subject I	Monitoring	Template (v 01S	ep2016).doc [Compatibilit	ty Mode] -	Word	Table	Tools				ā	- @ ×
File	Home	Insert	Design	Layout	References	Mailings	Review	View	ACROBAT	Design	Layout			Ν	lcAdams, John	A Share
File	Home				Subject Re Subject Re Subject inti Monitored a) Subject is b) Subject is c) Were all all requires g) AEs and documents. h) Were new Reporting P i) CTMS da j) Did any P k) Have all guidelines?	Views	Review SF Helen I SF Helen I get ID #SubjectSubjectSubject th correct IC res the CTMS d pretreatum firmed with confirmed timed confirmed sin CTMS communica es in OnCo ations or Ca Incidents b	View Diller Fara Data Safa 's Current 's Current 's courcent 's co	ACROBAT mily Comprei fety Monitorin Subject Revie	Design hensive Ca 1g Report ww rsing staff p to date. rectly? tion and e Safety ff yes:	Layout ncer Center a) Ye b) Ye c) Ye d) Ye g) Ye h) Ye j) Ye	r r s No s No	ant to do		tcAdams, John	Q Share ▲
Page 4 of 5	985 woi	rds Q2			CC#: Program: Version 7.0;	01Sep2016					Report	age 4 date: Monitoring Form				• 89%
	2				~ ~	L 0 <u>-</u>						🤹 🖂 🗴	<u>ي</u> ا ھ 🐫 📗 I		B 🕩 🛱	2:09 PM

₽ 5 -	÷ 10	DS	MC Subject	Monitoring	Template (v 01S	ep2016).doc [Compatibilit	y Mode] -	Word	Table	Tools		. 1	- 8 ×
File	Home	Insert	Design	Layout	References	Mailings	Review	View	ACROBAT	Design	Layout		McAdams, John	₽ Share
						UC		Data Saf	mily Compreh iety Monitorin Subject Revie	g Report	ncer Cente	er		*
					G. Overall Su	mmary Evalu	ation of Vis	it:						
					Satisfacto	ry								
					Acceptable	e with follow-	up items to	be compl	eted by the follo	owing date				
						-			to DSMC requir					
					DSMC. The	ctory, halt en HDFCCC DSN	rollment of IC Chair wil	new subje I notify th	cts, corrective e CHR regardin	action plan re g the results	equired with of this audi	hin 10 days to the it/monitoring visit		
						Aı	uditor's Sign	ature		Date	\mathbf{H}			
					Reviewed by: John F. McAe Manager, DS	lams, MS, CC	RP							
						Sij	gnature			Date				
					Approval: Thierry Jaha Chair, DSMC	:	gnature		$\overline{\mathcal{O}}$	Date		-		
					CC#: Program: Version 7.0;	01Sep2016					Repor	Page 5 rt date: Monitoring Form		
Page 5 of 5	985 wor	rds 🛱			version 7.0,	0106b2010		1117			Subject		5t	+ 89%
	e				ل كر	L 0 <u>-</u>	1 W					🖕 🔤 📴 🐫 🧞 😂 🚰	è 💽 🖪 🔶 📁 .	2:09 PM

Revision #3 (12Nov2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

Page 30 of 77


H 5-	Q ÷		DSMC Reg	julatory Revi	ew (01Sep2016)	(2).docx [Com	patibility Mc	ode] - Word	ł	Table	Tools			Œ	- 8 ×
File	Home	Insert	Design	Layout	References	Mailings	Review	View	ACROBAT	Design	Layout			McAdams, John	A₁ Share
					⊕Study 1	Title:		Data Safe Reç	r Family Con ety Monitorin gulatory Revi IRB Approva	g Report ew	e Cancer (Center			
					CC # :			UCSF	IRB Expiration	on Date:					
						ch Group:									
						al Investigato	or:								
					Auditor	tory CRC:	-		Site V	isit Date:					
					. ruurto				Site v.	Isit Date.		-			
							Areas of Rev	iew			Asses	ssments			
					Protocol										
					i b. H c. A	s the current iF RIS or filed in a Have all protoc Jated by the PI Are all prior UC RIS or filed in a	a zip drive? ol signature I (filed in OnC CSF IRB appr	pages beer Core or in a	n signed and	b. 🗖	Yes 🔲 No Yes 🔲 No Yes 🔲 No	,			
					Consent										
					b. A	or filed in a zip	drive? SF IRB appr		CF filed in iRIS	a. 🛄 Y b. 🛄 Y	es 🔲 No es 🔲 No				
					Investig	ator Brochur	re								
					b. Ar	s the current le e all prior IB ap drive?			a zip drive? i iRIS or filed in		es 🔲 No es 🔲 No				
						commercial, is ore or filed in a		insert on fi	le attached in	c. 🔲 Y	es 🔲 No				
						there iRIS doc owledgement/		of submissio	on on file with	d. 🔲 Y	es 🔲No				
					e. Tir	mely UCSF IRI	B submissior	n of IBs?		e. 🔲 Y	es 🔲 No				
					IND/IDE	Application	and FDA A	pproval							
					CC#: Program Report o						Vers	Page 1 Regulatory MVR ion 6.0, 01Sep2016			
Page 1 of 7	/ 1369 wo	rds 🖽													+ 89%
	A				入 」	L 0 <u>-</u>						🖕 🖂 📴 👢	🗼 🛛 🙃 🕟	🛬 💿 🖪 🚸 🕎	2:10 PM

Appendix H. Data and Safety Monitoring Reports: Regulatory Report

- ري ا	Q ÷		DSMC Reg	ulatory Revie	ew (01Sep2016)	(2).docx [Com	patibility Mo	de] - Word	I	Ta	ible Tools	s				E	- 8 ×
File	Home	Insert	Design	Layout	References	Mailings	Review	View	ACROBAT	Desig	n La	yout				McAdams, Johr	P₄ Share
					: b.	ls the initial app zip drive? Was the FDA C	olication on fi	Data Safe Reg le in OnCor Letter of IN		a. b.	TYes [
					c. 1	the IND)? Was the first pa receiving FDA	atient enrolle	d more thar		U.]Yes [□No					
					a. Whe	us: DI Hel Exemp en Pl holds the	ot IND, have th					□No					
						n filed as requi p drive) (If exer			in OnCore or o	n a. L	116						
					PRC Ap	provals											
					appr b. OnC c.	Did the PRC ap rovals? PRC approved core? PRC amendme umented in OnC	Protocol Ve	rsions are o col and SC	locumented in IC is	b.	Yes Yes Yes	No					
					UCSF IR	B Approvals											
					patients	Any lapses in U enrolled? RIS approvals o				a. [Yes N/A	No					
					initial sul c. if	bmission?	on file in iRIS	or filed in a	a zip drive for al		Yes Yes		N/A				
					d. F	Per ITR policy, i If for safety within 60 d	if Administral , was protoc	ive <u>Memo ;</u> ol amendeo	and approved	<u>d.</u> .	Yes	■No	N /A				
					CC#: Program Report							Versi	Page 2 Regulatory MVR on 6.0, 01Sep2016				
		p.m.												507			-
Page 2 of 7	/ 1369 wo	ords LJX									_	_					+ 89% 2:11 PM
🥶	e	1		2		<u>}</u>							• 🔤 🚥 🐫	් ම	💿 🕿 🛓 🕻	🖲 🕕 📜	10/30/2017

Revision #3 (12Nov2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

Page 32 of 77



Revision #3 (12Nov2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

Page 33 of 77

⊟ 5-	Q ÷		DSMC Reg	julatory Revi	ew (01Sep2016)	(2).docx [Com	patibility Mc	ode] - Word	l.	Tabl	e Tools				Ē	- @ ×
File	Home	Insert	Design	Layout	References	Mailings	Review	View	ACROBAT	Design	Layout			N	lcAdams, John	₽ Share
								Data Safe	r Family Co ty Monitorir gulatory Rev	ig Report	ve Cancer	Center				
					SAE Se	ction							1			
					a. docu	SAE reports to umentation (in	o the UCSF I	RB with su in a zip d	pporting - ive)?	a. 🗌	Yes 🔲 No					
					b. docu driv	SAE report to umentation/e-n e)?	Sponsor with nails (in OnC	h supportin ore or fiel	g d in a zip	b. 🔲	Yes 🔲 No					
					com	In a Multicente municate new s) in teleconfe	risks from th	e SAEs.to 1	ting site the participating fore or filed in	1	Yes 🔲 No	□ N/A				
					a zij	o drive)?				d. 🔲	Yes 🔲 No	N/A				
					subr e. supp		the coordinates the IND, we mentation) sur-	ating site a re <i>MedWa</i>	s per protocol? tch forms (with	e. 🔲	Yes 🔲 No					
					f											
					Protoco	l Violations ar	nd/or Incider	nt Reports								
						PVs reported t lines with supp			idelines and	a	Yes 🔲 No	5				
					Corresp	ondence										
					othe	Was all corres r sites (for mult I in a zip drive	icenter trials			a.	Yes 1	No				
					Study P	ersonnel										
						Coordinator train (UCSF IRB, CIT		n OnCore o	r filed in a zip	a.	Yes 🗌	No				
						drive).				b.	🗌 Yes 🔲	No				
					b. or fil	Staff delegation led in a zip driv	iog (filed in R e).	egulatory E	inder, OnCore		Yes 🔲	NT-				
					c. drive	CVs for all inves a).	tigators (filed	in OnCore	or filed in a zip		Yes I					
					CC#:					u.	1 1 65 [1]	Page 4	J			
					Program Report						Vers	Regulatory MVR sion 6.0, 01Sep2016				
																-
Page 4 of 7	1369 wo	ords 🖽						110							-	+ 89%
🥭	e				<u>لم</u>	۶ 🔁						🗣 🔤 📴 🜷	ම 🦣	۵ 🗟 🧟	B 🕩 🛱	2:12 PM 10/30/2017

Revision #3 (12Nov2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

Page 34 of 77

B 5-				ulatory Revi	ew (01Sep2016)	(2).docx [Com	patibility Mo	ode] - Wor	d	Tak	le Tools		Ē	- 8 ×
File	Home	Insert	Design	Layout	References	Mailings	Review	View	ACROBAT	Design	Layout		to do McAdams, Johr	A Share
								Data Saf	er Family Con ety Monitorin gulatory Revi	g Report		er Center		
					d. N	/ID licenses (file	ed in OnCore	or filed in a	a zip drive).					
					FDA For	ms 1571/1572								
					where the PI does r and signe b.	not hold the INI ad/dated by the Was the Form	IND) or Form D or Sponso e PI (filed in 1572 updat	n 1572 (for red trials) b OnCore or ed for staff	ISTS where the een completed in a zip drive)? or lab changes	a.	Yes	□No □N/A		
						able (filed in O	nCore or in a	a zip drive)	?	b.	L Yes		_	
					a. P AE review	v (Phase 1 – v	eekly reviev	v; Phase 2-	and/or Monthly monthly review)	a.	Tes Ves	No	-	
					ь. С	OnCore or file InCore Case R s (filed in OnC	eport Form (CRF) com		b.	🔲 Yes	No		
						ite Committee zip drive)?	Meeting Mir	nutes (filed	in OnCore or	c.	🔲 Yes	No		
					CC#: Program Report o						v	Page 5 Regulatory MVR ersion 6.0, 01Sep2016		
Page 5 of 7	1369 wo	rds Ω⊠					110	110						+ 89%
	6		0		2 1	L 0	w					💁 🔤 🚺	u 🍖 👁 💿 🕿 🛬 💽 🐠 🛫	2:13 PM

Revision #3 (12Nov2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

Page 35 of 77

B 5-	Q ±		DSMC Reg	julatory Revie	ew (01Sep2016)	(2).docx [Com	patibility Me	ode] - Word		Table	Tools				٦.	- 8 ×
File	Home	Insert	Design	Layout	References	Mailings	Review	View A	CROBAT	Design	Layout			Ma	Adams, John	A₁ Share
								elen Diller Fa Data Safety I Regula		ng Report	e Cancer	Center				
					New R							1				
						IND Safety Of	fety reports s and Safety	ved zip drive of {i.e., IBs, Extern letters} and		Yes	No					
					b)	IBs, External Letters? If ye revie man Wer	SAEs, Interna s, were these wed by the ner per ITR s e these new CSF IRB/ IRIS	afety policy? risks reported		Yes	No					
					Screen	ing and Enro	llment Log									
						Is there a So d in OnCore o		Enrollment Log ip drive?	a.	Yes N	0					
					Labs											
					Dr b.	Are the CLIA Core or file Are the CAI a zip drive)?	d in a zip d Ps (filed in			Yes N						
					or d.	filed in a zip	drive)?	led in OnCore	c.	Yes 🗖	Ĩo					
					e.		f the Lab D	n a zip drive) irector (filed in rive)?	d.	Yes 1						
									e.	Yes 🔲	No					
					CC#: Prograr Report						Ver	Page 6 Regulatory MVR sion 6.0, 01Sep2016				
Page 6 of 7	/ 1369 wo	ords 🖽													-	+ 89%
<u>@</u>	e				ی کر	٨	W					🔩 🖂 📴	් 🍖 🔊 () 🖪 🛬 🕥 🛛	• 🗊 .	2:13 PM 10/30/2017

Revision #3 (12Nov2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)


Page 36 of 77

H 51	÷ 10 -		DSMC Reg	ulatory Revi	ew (01Sep2016)	(2).docx [Com	patibility M	ode] - Wor	d	Table	Tools			ā.	- @ ×
File	Home	Insert	Design	Layout	References	Mailings	Review	View	ACROBAT	Design	Layout			McAdams, John	A Share
								Data Saf	er Family Cor ety Monitorir gulatory Rev	g Report	e Cancer (Center	-		•
					Commo <u>G. Ove</u>	ents: rall Summary:	<u>.</u>						-		
					Satis	-	llow-up iter	ns to be co	ompleted by the	following d	ate				
					Signi	ficant finding	s with follow	v-up respo	onse to DSMC r	equired					
					DSMC.	tisfactory, ha The HDFCCC	It enrollmer DSMC Cha	nt of new s ir will notif	ubjects, correc fy the CHR rega	tive action p arding the re	lan required sults of this	within 10 days to the audit/monitoring visit			
					Reviewe John F. Manage	d by: McAdams, MS r, DSMC	Auditor's	Signature			Date				
					Approv Thierry Chair, I	Jahan, MD	Signature	X		— i	Date				
							Simusture			;	Date				
							Signature				Jaid				
					CC#:							Page 7			
					Progran Report o						Vers	Regulatory MVR sion 6.0, 01Sep2016			
Page 7 of 7	7 1369 wo	ords 🖽												5	▼ + 89%
	6		O		۵	L 0 <u>-</u>	W] 🦉	3			🗣 🖂 📭	u 🖡 🕹 🕞 🖌	- 	2:14 PM

Revision #3 (12Nov2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)


Page 37 of 77

Appendix I: DSMC Remediation Process: Study Program Accrual Hold



Page 38 of 77

Appendix J: DSMC Remediation Process: Study Program Accrual Reopening



Revision #3 (12Nov2017) Approved by NCI (09Feb2012) Revision #2 (05Oct2011) Approved by NCI (23Aug2007) Revision #1 01May/2002 Approved by NCI (19Aug2002)

Page 39 of 77

Appendix K. Model DSMP Templates for Investigators to Insert into Protocols

Note to Investigators: These plans are templates for your funding applications and for your protocol preparation.

Please contact the DSMC for updated templates.

Page 40 of 77

Appendix K.1 (Single Site) Data and Safety Monitoring Plan for a Phase I Dose Escalation Institutional Study

1. Oversight and Monitoring Plan

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and patient safety for all HDFCCC institutional clinical studies. A summary of DSMC activities for this study includes:

- Review of patient data in each cohort.
- Review of serious adverse events.
- Approval of dose escalation by DSMC Chair, or Vice Chair.
- Real-time monitoring (depending on study accrual).
- Minimum of a yearly regulatory audit.

2. Monitoring and Reporting Guidelines

Investigators will conduct continuous review of data and patient safety and discuss each patient's treatment at weekly site committee meetings. The discussions are documented in the site committee meeting minutes. For each dose level, the discussion will include the number of patients, significant toxicities in accordance with the protocol, doses adjustments, and observed responses.

All institutional Phase I therapeutic studies are designated with a high-risk assessment (see Appendix H). The data for each patient is monitored by a DSMC monitor in real time as patients are enrolled and includes all visits through the first post-Dose Limiting Toxicity (DLT) visit.

3. Review and Oversight Requirements

Page 41 of 77

3.1 Adverse Event Monitoring

All clinically significant adverse events (AEs), whether or not considered expected or unexpected and whether or not considered associated with the use of the study drug, will be entered into OnCore®, UCSF's Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to treatment or medical procedure. Attribution categories are:

- **Definite** The adverse event is clearly related to the investigational agent(s) or medical procedure.
- **Probable** The adverse event is likely related to the investigational agent(s) or medical procedure.
- **Possible** The adverse event may be related to the investigational agent(s) or medical procedure.
- **Unlikely** The adverse event is doubtfully related to the investigational agent(s) or medical procedure.
- **Unrelated** the adverse event is clearly not related to the investigational agent(s) or medical procedure.

All clinically significant adverse events entered into OnCore® will be reviewed on a weekly basis at the site committee meetings. The site committee will review and discuss the selected toxicity, the toxicity grade, and the attribution of relationship of the adverse event to the administration of the study drug(s).

3.2 Serious Adverse Event Reporting

By definition, an Adverse Event is defined as a Serious Adverse Event (SAE) according to the following criteria:

- Death.
- Life-threatening (i.e., results in an immediate risk of death).
- Requires inpatient hospitalization or prolongation of existing hospitalization.
- Permanent or significant disability/incapacity.
- Gives rise to a congenital anomaly/birth defect, or cancer, or any experience that suggests a significant hazard, contraindication, side effect, or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above.
- Event occurring in a gene therapy study.

Page 42 of 77

- Event that changes the risk/benefit ratio of a study.
- Any other event the Principal Investigator judges to be serious or which would suggest a significant hazard, contraindication, side effect, or precaution

Serious Adverse Event reporting will be in accordance with all UCSF IRB Regulations and Code of Federal Regulation Title 21 Part 312.32. The SAE will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events:

https://irb.ucsf.edu/adverse-event

FDA website for guidance in reporting serious adverse events:

www.fda.gov/Safety/MedWatch/HowToReport/default.htm

Med Watch forms and information:

www.fda.gov/medwatch/getforms.htm

All Serious Adverse Events are entered into OnCore®, as well as submitted to the IRB (per IRB guidelines) via iRIS®. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at the DSMC meetings, which take place every six (6) weeks. The date the SAE was sent to all required reporting agencies will be documented in OnCore®.

If a death occurs during the treatment phase of the study, or within 30 days after the last administration of the study drug(s), and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Principal Investigator or his/her designee must notify the DSMC Chair or his qualified alternate within 1 business day.

The reporting procedure is by communication via phone or in person with written documentation of the one-on-one communication, via e-mail, with a copy of the e-mail sent to the DSMC Manager.

3.3 Dose Escalations

At the time of dose escalation, a written report will be submitted to the DSMC Chair (or Vice Chair) describing the cohorts, dose levels, adverse events, safety reports, and any Dose Limiting Toxicities (DLTs) observed, in accordance with the protocol. The report

Page 43 of 77

will be reviewed by the DSMC Chair or Vice Chair and written authorization to proceed or a request for more information will be issued within two business days of the request. The report is then reviewed at the subsequent DSMC meeting. In the event that the committee does not concur with the DSMC Chair's decision, study accrual is held while further investigation takes place.

3.4 Review of Adverse Event Rates

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Principal Investigator will notify the DSMC at the time the increased rate is identified. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the Investigator stops enrollment or stops the study due to safety issues, the DSMC Chair and DSMC Manager must be notified within 1 business day via e-mail. and the IRB must be notified within 10 business days via an iRIS Reporting Form.

Data and Safety Monitoring Committee Contacts:

Thierry Jahan, MD (DSMC Chair) 415-885-3792 Thierry.jahan@ucsf.edu Box 1705 UCSF HDFCCC San Francisco, CA 94158

DSMC Monitors Box 0128 UCSF HDFCCC San Francisco, CA 94143

Page 44 of 77

Appendix K.2 (Single Site) Data and Safety Monitoring Plan for a High Risk Vaccine or Gene-Therapy Institutional Study

1. Oversight and Monitoring Plan

The UCSF Helen Diller Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and patient safety for all HDFCCC institutional clinical studies. A summary of DSMC activities for this study includes:

- Review of all patient data.
- Review of serious adverse events.
- Real-time monitoring (depending on study accrual)
- Minimum of a yearly regulatory audit

2. Monitoring and Reporting Guidelines

Investigators will conduct continuous review of data and patient safety at weekly site committee meetings where the results of each patient's treatment are discussed and documented in the site committee minutes. The discussion will include the number of patients, significant toxicities as described in the protocol and observed responses.

All institutional vaccine or gene therapy therapeutic studies are deemed with a high-risk assessment (see Appendix H). The data is monitored by a DSMC Monitor in real-time as patients are enrolled in the trial through the first cycle of study drug therapy. All patients enrolled in the trial are monitored through the first cycle of therapy.

3. Review and Oversight Requirements

3.1 Adverse Event Monitoring

All clinically significant adverse events (AEs), whether or not considered to be expected or unexpected and whether or not considered to be associated with the use of the study drug, will be entered into OnCore®, UCSF's Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) (version 4.03) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to treatment or medical procedure. Attribution categories are:

Page 45 of 77

- **Definite** The adverse event is clearly related to the investigational agent(s) or medical procedure.
- **Probable** The adverse event is likely related to the investigational agent(s) or medical procedure.
- **Possible** The adverse event may be related to the investigational agent(s) or medical procedure.
- **Unlikely** The adverse event is doubtfully related to the investigational agent(s) or medical procedure.
- **Unrelated** the adverse event is clearly not related to the investigational agent(s) or medical procedure.

All adverse events entered into OnCore® will be reviewed on a weekly basis at the site committee meetings. The site committee will review and discuss the selected toxicity, the toxicity grade, and the attribution of relationship of the adverse event to the administration of the study drug(s).

3.2 Serious Adverse Event Reporting

By definition, an Adverse Event is defined as a Serious Adverse Event (SAE) according to the following criteria:

- Death.
- Life-threatening (i.e., results in an immediate risk of death).
- Requires inpatient hospitalization or prolongation of existing hospitalization
- Permanent or significant disability/incapacity.
- Gives rise to a congenital anomaly/birth defect, or cancer, or any experience that suggests a significant hazard, contraindication, side effect, or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above.
- Event occurring in a gene therapy study.
- Event that changes the risk/benefit ratio of a study.
- Any other event the Principal Investigator judges to be serious or which would suggest a significant hazard, contraindication, side effect, or precaution.

Serious Adverse Event reporting will be in accordance with the UCSF IRB Regulations and Code of Federal Regulation Title 21 Part 312.32. The SAE will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events:

https://irb.ucsf.edu/adverse-event

Page 46 of 77

FDA website for guidance in reporting serious adverse events:

www.fda.gov/Safety/MedWatch/HowToReport/default.htm

Med Watch forms and information:

www.fda.gov/medwatch/getforms.htm

All Serious Adverse Events are entered into OnCore®, as well as submitted to the IRB (per IRB guidelines) via iRIS®. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at the DSMC meetings, which take place every six (6) weeks. The date the SAE was sent to all required reporting agencies will be documented in OnCore®.

If a death occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s) and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Investigator or his/her designee must notify the DSMC Chair or Vice Chair within 1 business day.

The reporting procedure is by communication via phone or in person with written documentation of the one-on-one communication via e-mail, with a copy of the e-mail sent to the DSMC Manager.

3.3 Review of Adverse Event Rates

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Principal Investigator will notify the DSMC at the time the increased rate is identified. The report will indicate if the incident of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the Investigator stops enrollment or stops the study due to safety issues, the DSMC Chair and DSMC Manager must be notified within 1 business day via e-mail and the IRB must be notified via an iRIS Reporting Form.

Data and Safety Monitoring Committee Contacts:

Page 47 of 77

:

Thierry Jahan, MD (DSMC Chair) 415-885-3792 Thierry.jahan@ucsf.edu Box 1705 UCSF HDFCCC San Francisco, CA 94158

DSMC Monitors Box 0128 UCSF HDFCCC San Francisco, CA 94143

Page 48 of 77

Appendix K.3 (Single Site) Data and Safety Monitoring Plan for a Phase II or III Institutional Study

1. Oversight and Monitoring Plan

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and subject safety for all HDFCCC institutional clinical studies. A summary of DSMC activities for this study includes:

- Review of patient data.
- Review of serious adverse events.
- Auditing every six months (depending on study accrual).
- Minimum of a yearly regulatory audit.

2. Monitoring and Reporting Guidelines

Investigators will conduct continuous review of data and patient safety and discuss each patient's treatment at monthly site committee meetings. These discussions are documented in the site committee meeting minutes. The discussion will include the number of patients, significant toxicities in accordance with the protocol, and observed responses.

All institutional Phase II and III studies are designated with a moderate risk assessment (see Appendix H). The data is audited twice per year with twenty percent of the patients monitored (or at least three patients if the calculated value is less than three).

3. Review and Oversight Requirements

3.1 Adverse Event Monitoring

All Grade 3-5 Adverse Events (AEs), whether or not considered to be expected or unexpected and whether or not considered to be associated with the use of the study drug, will be entered into OnCore®, UCSF's Clinical Trial Management System.

Adverse Events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) (version 4.03) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to treatment or medical procedure. Attribution categories are:

Page 49 of 77

- **Definite** The adverse event is clearly related to the investigational agent(s) or medical procedure.
- **Probable** The adverse event is likely related to the investigational agent(s) or medical procedure.
- **Possible** The adverse event may be related to the investigational agent(s) or medical procedure.
- **Unlikely** The adverse event is doubtfully related to the investigational agent(s) or medical procedure.
- **Unrelated** the adverse event is clearly not related to the investigational agent(s) or medical procedure.

All Grade 3-5 adverse events entered into OnCore® will be reviewed on a monthly basis at the Site Committee meetings. The Site Committee will review and discuss the selected toxicity, the toxicity grade, and the attribution of relationship of the adverse event to the administration of the study drug(s).

3.2 Serious Adverse Event Reporting

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

- Death.
- Life-threatening (i.e. results in an immediate risk of death).
- Requires inpatient hospitalization or prolongation of existing hospitalization,
- Permanent or significant disability/incapacity
- Gives rise to a congenital anomaly/birth defect, or cancer, or any experience that suggests a significant hazard, contraindication, side effect, or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above.
- Event occurring in a gene therapy study.
- Event that changes the risk/benefit ratio of a study.
- Any other event the Principal Investigator judges to be serious or which would suggest a significant hazard, contraindication, side effect, or precaution.

Serious Adverse Event reporting will be in accordance with the UCSF IRB Regulations and Code of Federal Regulation Title 21 Part 312.32. The SAE will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events:

https://irb.ucsf.edu/adverse-event

FDA website for guidance in reporting serious adverse events: Page 50 of 77

www.fda.gov/Safety/MedWatch/HowToReport/default.htm

Med Watch forms and information:

www.fda.gov/medwatch/getforms.htm

All serious adverse events are entered into OnCore®, as well as submitted to the IRB (per IRB guidelines) via iMedRIS®. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every six weeks. The date the SAE is sent to all required reporting agencies will be documented in OnCore®.

If the SAE involves a subject death, and is determined to be possibly, probably or definitely related to the investigational drug or any research related procedure, the event must be reported to the DSMC Chair or Vice Chair within 1 business day.

The reporting procedure is by communication via phone or in person with written documentation of the one-on-one communication via e-mail, with a copy of the e-mail to the DSMC Manager.

3.3 Review of Adverse Event Rates

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Principal Investigator will notify the DSMC at the time the increased rate is identified. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the Investigator stops enrollment or stops the study due to safety issues, the DSMC Chair and DSMC Manager must be notified within 1 business day via e-mail. and the IRB must be notified within 10 business days via an iRIS Reporting Form.

Data and Safety Monitoring Committee Contacts:

Thierry Jahan, MD 415-885-3792 Thierry.jahan@ucsf.edu Box 1705 UCSF HDFCCC San Francisco, CA 94158

Page 51 of 77

DSMC Monitors Box 0128 UCSF HDFCCC San Francisco, CA 94143

Page 52 of 77

Appendix K.4 (Single Site) Data and Safety Monitoring Plan for a Nontherapeutic Institutional Study

1. Oversight and Monitoring Plan

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and patient safety for all HDFCCC institutional clinical studies. A summary of DSMC activities for this study includes:

- Review of patient data.
- Review of serious adverse events.
- Auditing on a yearly basis.
- Minimum of a yearly regulatory audit.

The UCSF HDFCCC Data and Safety Monitoring Committee (DSMC) is responsible for subject safety for all HDFCCC institutional clinical studies. Nontherapeutic studies are characterized as low risk studies due to the study design, as there isn't administration of drugs or complementary therapy that put the patient at significant risk. Twenty percent of all enrolled subjects will be audited once per year.

2. Monitoring and Reporting Guidelines

Investigators will conduct continuous review of data and patient safety at monthly Site Committee meetings. The risk assessment for this type of trial is low; hence, the study would be audited only once per year, with 20 percent of the enrolled subject being selected for audit.

3. Review and Oversight Requirements

3.1 Adverse Event Monitoring

All clinically significant adverse events (AEs), whether or not considered to be expected or unexpected and whether or not considered to be associated with the use of the study drug, will be entered into OnCore®, UCSF's Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to treatment or medical procedure. Attribution categories are:

Page 53 of 77

- **Definite** The adverse event is clearly related to the investigational agent(s) or medical procedure.
- **Probable** The adverse event is likely related to the investigational agent(s) or medical procedure.
- **Possible** The adverse event may be related to the investigational agent(s) or medical procedure.
- **Unlikely** The adverse event is doubtfully related to the investigational agent(s) or medical procedure.
- **Unrelated** the adverse event is clearly not related to the investigational agent(s) or medical procedure.

All clinically significant adverse events entered into OnCore® will be reviewed on a monthly basis at the Site Committee meetings

3.2 Serious Adverse Event Reporting

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

- Death.
- Life-threatening (i.e., results in an immediate risk of death).
- Requires inpatient hospitalization or prolongation of existing hospitalization.
- Permanent or significant disability/incapacity.
- Gives rise to a congenital anomaly/birth defect, or cancer, or any experience that suggests a significant hazard, contraindication, side effect, or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above.
- Event occurring in a gene therapy study.
- Event that changes the risk/benefit ratio of a study.
- Any other event the Principal Investigator judges to be serious or which would suggest a significant hazard, contraindication, side effect, or precaution.

Serious Adverse Event reporting will be in accordance with the UCSF IRB Regulations and Code of Federal Regulation Title 21 Part 312.32. The SAE will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events:

https://irb.ucsf.edu/adverse-event

FDA website for guidance in reporting serious adverse events:

Page 54 of 77

www.fda.gov/Safety/MedWatch/HowToReport/default.htm

Med Watch forms and information:

www.fda.gov/medwatch/getforms.htm

All Serious Adverse Events are entered into OnCore®, as well as submitted to the IRB via iRIS®. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every six (6) weeks. The date the SAE was sent to all required reporting agencies will be documented in OnCore®.

If a death occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s) and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Investigator or his/her designee must notify the DSMC Chair or Vice Chair within 1 business day. The reporting procedure is by communication via phone or in person with written documentation of the one-on-one communication via e-mail, with a copy of the e-mail to the DSMC Manager.

3.3 Review of Adverse Event Rates

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Principal Investigator will notify the DSMC at the time the increased rate is identified. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the Investigator stops enrollment or stops the study due to safety issues, the DSMC Chair and DSMC Manager must be notified within 1 business day and the IRB must be notified within 10 business days.

Data and Safety Monitoring Committee Contacts:

Thierry Jahan, MD 415-885-3792 Thierry.jahan@ucsf.edu Box 1705 UCSF HDFCCC San Francisco, CA 94158

Page 55 of 77

DSMC Monitors Box 0128 UCSF HDFCCC San Francisco, CA 94143

Page 56 of 77

Appendix K.5 (Multicenter) Data and Safety Monitoring Plan for a Non-Therapeutic Multicenter Institutional Study

1. Oversight and Monitoring Plan

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and patient safety for all HDF CCC institutional clinical studies. A summary of DSMC activities for this study includes:

- Review of patient data.
- Review of serious adverse events.
- Auditing on a yearly basis.
- Minimum of a yearly regulatory audit.

The UCSF HDFCCC Data and Safety Monitoring Committee (DSMC) is responsible for subject safety for all HDFCCC institutional clinical studies. Nontherapeutic studies are characterized as low risk studies due to the study design, as there is not administration of drugs or complementary therapy that put the patient at significant risk. Twenty percent of all enrolled subjects will be audited once per year.

The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites to communicate the review of adverse events, safety data, and other study matters.

The Principal Investigator at the UCSF Coordinating Center will hold the role of Study Chair. The Study Chair is responsible for the overall conduct of the study and for monitoring its safety and progress at all participating sites. The Study Chair will conduct continuous review of data and patient safety and discuss each patient's treatment at monthly UCSF Site Committee meetings. The discussions are documented in the UCSF Site Committee meeting minutes.

2. <u>Multicenter communication</u>

The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites. The following issues will be discussed as appropriate:

• Enrollment information.

Page 57 of 77

- Adverse Events (i.e., new adverse events and updates on unresolved adverse events and new safety information).
- Protocol Violations.
- Other issues affecting the conduct of the study.

Adverse events reporting to the DSMC will include reports from both the UCSF Coordinating Center, as well as the participating sites. The DSMC will be responsible for monitoring all data entered in OnCore® at the UCSF Coordinating Center and the participating sites as per the study-specific guidelines listed in Appendix H. The data (i.e., copies of source documents) from the participating sites will be downloaded into the PC console of OnCore prior to the monitoring visits in order for the DSMC to monitor the participating site's compliance with the protocol and FDA regulations.

3 Review and Oversight Requirements

3.1 Adverse Event Monitoring

All Grade 3-5 Adverse Events (AEs), regardless of being unexpected or considered to be associated with the use of the study drug will be entered into OnCore®, UCSF's Clinical Trial Management System.

Adverse Events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse Events are further given an assignment of attribution or relationship to treatment or medical procedure. Attribution categories are:

- **Definite** The adverse event is clearly related to the investigational agent(s) or medical procedure.
- **Probable** The adverse event is likely related to the investigational agent(s) or medical procedure.
- **Possible** The adverse event may be related to the investigational agent(s) or medical procedure.
- **Unlikely** The adverse event is doubtfully related to the investigational agent(s) or medical procedure.
- **Unrelated** the adverse event is clearly not related to the investigational agent(s) or medical procedure.

All Grade 3-5 adverse events entered into OnCore® will be reviewed on a monthly basis at the UCSF Site Committee meetings. All adverse events entered into OnCore® will be reviewed on a monthly basis at the UCSF Coordinating Center Site Committee meetings.

All clinically significant adverse events must be reported to the UCSF Coordinating Page 58 of 77

Center by the participating sites within 10 business days of becoming aware of the event or during the next scheduled monthly conference call, whichever is sooner. The UCSF Site Committee will review and discuss the selected toxicity, the toxicity grade, and the attribution of relationship of the adverse event to the administration of the study drug(s) from the UCSF Coordinating Center and the participating sites.

3.2 Serious Adverse Event Reporting

By definition, an Adverse Event is defined as a Serious Adverse Event (SAE) according to the following criteria:

- Death.
- Life-threatening (i.e. results in an immediate risk of death).
- Requires inpatient hospitalization or prolongation of existing hospitalization.
- Permanent or significant disability/incapacity.
- Gives rise to a congenital anomaly/birth defect, or cancer, or any experience that suggests a significant hazard, contraindication, side effect, or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above.
- Event occurring in a gene therapy study.
- Event that changes the risk/benefit ratio of a study.
- Any other event the Principal Investigator judges to be serious or which would suggest a significant hazard, contraindication, side effect, or precaution.

Serious Adverse Event reporting will be in accordance with the UCSF IRB Regulations and Code of Federal Regulation Title 21 Part 312.32. The SAE will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events:

https://irb.ucsf.edu/adverse-event

FDA website for guidance in reporting serious adverse events:

www.fda.gov/Safety/MedWatch/HowToReport/default.htm

Med Watch forms and information:

www.fda.gov/medwatch/getforms.htm

All Serious Adverse Events are entered into OnCore®, as well as submitted to the IRB (per IRB guidelines) via iRIS®. All SAEs, whether expected or unexpected, must be Page 59 of 77

reported to the UCSF Coordinating Center within 1-business day of becoming aware of the event. The SAEs are reviewed and monitored by the UCSF Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every six weeks. The date the SAE was sent to all required reporting agencies will be documented in OnCore®.

If a death occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s) and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Study Chair at the UCSF Coordinating Center or the assigned designee must be notified within 1 business day from the participating site(s) and the Study Chair must then notify the DSMC Chair or qualified alternate within 1 business day of this notification. The reporting procedure is by communication via phone or in person with written documentation of the one-on-one communication via e-mail, with a copy of the e- mail to the DSMC Manager.

3.3 Review of Adverse Event Rates

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Study Chair at the UCSF Coordinating Center is responsible for notifying the DSMC at the time the increased rate is identified. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the Study Chair stops enrollment or stops the study due to safety issues, the DSMC Chair and DSMC Manager must be notified within 1 business day and the IRB must be notified within 10 business days via an iRIS Reporting Form.

Data and Safety Monitoring Committee Contacts:

Thierry Jahan, MD (DSMC Chair) 415-885-3792 Thierry.jahan@ucsf.edu Box 1705 UCSF HDFCCC San Francisco, CA 94158

Page 60 of 77

DSMC Monitors Box 0128 UCSF HDFCCC San Francisco, CA 94143

Page 61 of 77

Appendix K.6 (Multicenter) Data and Safety Monitoring Plan for a Multicenter Institutional Study (Phase 1 Dose Escalation)

1. Oversight and Monitoring Plan

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and patient safety for all HDFCCC institutional clinical studies. A summary of DSMC activities for this study includes:

- Review of patient data in each cohort.
- Review of serious adverse events.
- Approval of dose escalation by DSMC Chair or Vice Chair.
- Real time monitoring (depending on study accrual).
- Minimum of a yearly regulatory audit.

2. Monitoring and Reporting Guidelines

All institutional Phase I therapeutic studies are designated with a high risk assessment (see Appendix H). The data is monitored by a DSMC monitor once a month as patients are enrolled and includes all visits through the first post-Dose Limiting Toxicity (DLT) period. At the time of dose escalation, a written report will be submitted to the DSMC Chair outlining the cohort dose, all adverse events and serious adverse event reports, and any Dose Limiting Toxicity as described in the protocol. The report will be reviewed by the DSMC Chair or qualified alternate and written authorization to proceed or a request for more information will be issued within two business days of the request. The report is then reviewed at the subsequent DSMC meeting. In the event that the committee does not concur with the DSMC Chair's decision, further study accrual is held while further investigation takes place.

The Principal Investigator at the UCSF Coordinating Center will hold the role of Study Chair. The Study Chair is responsible for the overall conduct of the study and for monitoring its safety and progress at all participating sites. The Study Chair will conduct continuous review of data and patient safety and discuss each patient's treatment at weekly UCSF Site Committee meetings. The discussions are documented in the UCSF Site Committee meeting minutes. For each dose level, the discussion will include the number of patients, significant toxicities in accordance with the protocol, doses adjustments, and observed responses.

Multicenter communication

The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Page 62 of 77

Coordinating Center will also coordinate monthly conference calls with the participating sites. The following issues will be discussed as appropriate:

- Enrollment information.
- Cohort updates (i.e., DLTs).
- Adverse events (i.e. new adverse events and updates on unresolved adverse events and new safety information).
- Protocol violations.
- Other issues affecting the conduct of the study.

Dose Level Considerations

The PI/Study Chair, participating investigators, and research coordinators from each site will review enrollment for each dose level cohort during the regularly scheduled conference calls. The dose level for ongoing enrollment will be confirmed for each patient scheduled to be enrolled at a site. Dose level assignments for any patient scheduled to begin treatment must be confirmed by the UCSF Coordinating Center via e-mail.

If a Dose Limiting Toxicity (DLT) arises in a patient treated at a participating site, all sites must be notified immediately by the UCSF Coordinating Center. The Study Chair has 1 business day (after first becoming aware of the event at either the UCSF Coordinating Center or the participating site) in which to report the information to all participating sites. If the DLT occurs at a participating site, the local investigator must report it to the UCSF Coordinating Center within one business day, after which the UCSF Coordinating Center will notify the other participating sites.

Adverse events reporting to the DSMC will include reports from both the UCSF Coordinating Center, as well as the participating sites. The DSMC will be responsible for monitoring all data entered in OnCore® at the UCSF Coordinating Center and the participating sites as per the study-specific guidelines listed in Appendix H. The data (i.e., redacted copies of source documents) from the participating sites will be downloaded into the PC console of OnCore prior to the monitoring visits in order for the DSMC to monitor the participating site's compliance with the protocol and FDA guidelines.

3. Review and Oversight Requirements

3.1 Adverse Event Monitoring

All clinically significant adverse events (AEs), whether or not considered to be expected or unexpected and whether or not considered to be associated with the use of study drug, will be entered into OnCore®, UCSF's Clinical Trial Management System.

Page 63 of 77

Adverse Events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse Events are further given an assignment of attribution or relationship to treatment or medical procedure. Attribution categories are:

- **Definite** The adverse event is clearly related to the investigational agent(s) or medical procedure.
- **Probable** The adverse event is likely related to the investigational agent(s) or medical procedure.
- **Possible** The adverse event may be related to the investigational agent(s) or medical procedure.
- **Unlikely** The adverse event is doubtfully related to the investigational agent(s) or medical procedure.
- **Unrelated** the adverse event is clearly not related to the investigational agent(s) or medical procedure.

All adverse events entered into OnCore® will be reviewed on a weekly basis at the UCSF Coordinating Center's Site Committee. All clinically significant adverse events must be reported to the UCSF Coordinating Center by the participating sites within 1 business days of becoming aware of the event. The Site Committee will review and discuss the selected toxicity, the toxicity grade, and the attribution of relationship of the adverse event to the administration of the study drug(s) from the UCSF Coordinating Center and the participating sites.

3.2 Serious Adverse Event Reporting

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

- Death.
- Life-threatening (i.e. results in an immediate risk of death).
- Requires inpatient hospitalization or prolongation of existing hospitalization.
- Permanent or significant disability/incapacity.
- Gives rise to a congenital anomaly/birth defect, or cancer, or any experience that suggests a significant hazard, contraindication, side effect, or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above.
- Event occurring in a gene therapy study.
- Event that changes the risk/benefit ratio of a study.

Page 64 of 77

• Any other event the Principal Investigator judges to be serious or which would suggest a significant hazard, contraindication, side effect, or precaution.

Serious adverse event reporting will be in accordance with the UCSF IRB Regulations and Code of Federal Regulation Title 21 Part 312.32. The SAE will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events:

https://irb.ucsf.edu/adverse-event

FDA website for guidance in reporting serious adverse events:

www.fda.gov/Safety/MedWatch/HowToReport/default.htm

Med Watch forms and information:

www.fda.gov/medwatch/getforms.htm

All serious adverse events are entered into OnCore®, as well as submitted to the IRB (per IRB guidelines) via iRIS®. All SAEs, whether expected or unexpected, must be reported to the UCSF Coordinating Center within 10 business days of becoming aware of the event or during the next scheduled conference all, whichever is sooner. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every six weeks. The date the SAE was sent to all required reporting agencies will be documented in OnCore®.

If a death occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s) and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Study Chair at the UCSF Coordinating Center or the assigned designee must be notified within 1 business day from the participating site(s) and the Study Chair must then notify the DSMC Chair or qualified alternate within 1 business day of this notification. The reporting procedure is by communication via e-mail, with a copy of the e-mail to the DSMC Manager.

3.3 Review of Adverse Event Rates

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Study Chair at the UCSF Coordinating Center is responsible for notifying the DSMC at the time the

increased rate is identified. The report will indicate if the incidence of adverse events Page 65 of 77

observed in the study is above the range stated in the Investigator's Brochure or package insert.

If at any time the Study Chair stops enrollment or stops the study due to safety issues, the DSMC Chair and DSMC Manager must be notified within 1 business day via e-mail and the IRB must be notified via 10 business days via an iRIS Reporting Form.

Data and Safety Monitoring Committee Contacts:

Thierry Jahan, MD (DSMC Chair) 415-885-3792 Thierry.jahan@ucsf.edu Box 1705 UCSF HDFCCC San Francisco, CA 94158

DSMC Monitors Box 0128 UCSF HDFCCC San Francisco, CA 94143

Page 66 of 77

Appendix K.7 (Multicenter) Data Safety Monitoring Plan for Vaccine or Gene Therapy Multicenter Study

1. Oversight and Monitoring Plan

The UCSF-Helen Diller Family Comprehensive Cancer Center (HDF CCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and patient safety for all HDF CCC institutional clinical studies. A summary of DSMC activities for this study includes:

- Review of all patient data.
- Review of serious adverse events.
- Real time monitoring (depending on study accrual).
- Minimum of a yearly regulatory audit.

2. Monitoring and Reporting Guidelines

All institutional vaccine or gene therapy therapeutic studies are designated with a high-risk assessment (see Appendix H). The data is monitored by a DSMC Monitor in real-time as patients are enrolled in the trial through the first cycle of study drug therapy. All patients enrolled in the trial are monitored through the first cycle of therapy.

The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites to communicate the review of adverse events, safety data, and other study matters.

The Principal Investigator at the UCSF Coordinating Center will hold the role of Study Chair. The Study Chair is responsible for the overall conduct of the study and for monitoring its safety and progress at all participating sites. The Study Chair will conduct continuous review of data and patient safety and discuss each patient's treatment at weekly UCSF Site Committee meetings. The discussions are documented in the UCSF Site Committee meeting minutes.

Multicenter communication

The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites. The following issues will be discussed as appropriate:

Page 67 of 77

- Enrollment information.
- Adverse Events (i.e., new adverse events and updates on unresolved adverse events and new safety information).
- Protocol Violations.
- Other issues affecting the conduct of the study.

Adverse events reporting to the DSMC will include reports from both the UCSF Coordinating Center, as well as the participating sites. The DSMC will be responsible for monitoring all data entered in OnCore® at the UCSF Coordinating Center and the participating sites as per the study-specific guidelines listed in Appendix H. The data (i.e., redacted copies of source documents) from the participating sites will be downloaded into the PC module of OnCore® prior to the monitoring visits in order for the DSMC to monitor the participating site's compliance with the protocol and FDA guidelines.

3. Review and Oversight Requirement

3.1 Adverse Event Monitoring

All clinically significant adverse events (AEs), whether or not considered to be expected or unexpected and whether or not considered to be associated with the use of study drug, will be entered into OnCore®, UCSF's Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse Events are further given an assignment of attribution or relationship to treatment or medical procedure. Attribution categories are:

- **Definite** The adverse event is clearly related to the investigational agent(s) or medical procedure.
- **Probable** The adverse event is likely related to the investigational agent(s) or medical procedure.
- **Possible** The adverse event may be related to the investigational agent(s) or medical procedure.
- **Unlikely** The adverse event is doubtfully related to the investigational agent(s) or medical procedure.
- **Unrelated** the adverse event is clearly not related to the investigational agent(s) or medical procedure.

Page 68 of 77

All adverse events entered into OnCore® will be reviewed on a weekly basis at the UCSF Coordinating Center Site Committee meetings. All clinically significant adverse events must be reported to the UCSF Coordinating Center by the participating sites within 10 business days of becoming aware of the event or during the next scheduled monthly conference call, whichever is sooner. The UCSF Site Committee will review and discuss the selected toxicity, the toxicity grade, and the attribution of relationship of the adverse event to the administration of the study drug(s) from the UCSF Coordinating Center and the participating sites.

3.2 Serious Adverse Event Reporting

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

- Death.
- Life-threatening (i.e. results in an immediate risk of death).
- Requires inpatient hospitalization or prolongation of existing hospitalization.
- Permanent or significant disability/incapacity.
- Gives rise to a congenital anomaly/birth defect, or cancer, or any experience that suggests a significant hazard, contraindication, side effect, or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above.
- Event occurring in a gene therapy study.
- Event that changes the risk/benefit ratio of a study.
- Any other event the Principal Investigator judges to be serious or which would suggest a significant hazard, contraindication, side effect, or precaution.

Serious Adverse Event reporting will be in accordance with the UCSF IRB Regulations and Code of Federal Regulation Title 21 Part 312.32. The SAE will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events:

https://irb.ucsf.edu/adverse-event

FDA website for guidance in reporting serious adverse events:

www.fda.gov/Safety/MedWatch/HowToReport/default.htm

Med Watch forms and information:

Page 69 of 77

www.fda.gov/medwatch/getforms.htm

All serious adverse events are entered into OnCore®, as well as submitted to the IRB (per IRB) guidelines via iRIS®. All SAEs, whether expected or unexpected, must be reported to the UCSF Coordinating Center within 1 business days of becoming aware of the event. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every six weeks. The date the SAE was sent to all required reporting agencies will be documented in OnCore®.

If a death occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s) and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Study Chair at the UCSF Coordinating Center or the assigned designee must be notified within 1 business day from the participating site(s) and the Study Chair must then notify the DSMC Chair or qualified alternate within 1 business day of this notification. The reporting procedure is by communication via phone or in person with written documentation of the one-on-one communication via e-mail, with a copy of the e-mail to the DSMC Manager.

3.3 Review of Adverse Event Rates

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Study Chair at the UCSF Coordinating Center is responsible for notifying the DSMC at the time the increased rate is identified. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the Study Chair stops enrollment or stops the study due to safety issues, the DSMC Chair and DSMC Manager must be notified within 1 business day via e-mail and the IRB must be notified within 10 business days via an iRIS Reporting Form.

Data and Safety Monitoring Committee Contacts:

Thierry Jahan, MD 415-885-3792 Thierry.jahan@ucsf.edu Box 1705 UCSF HDFCCC San Francisco, CA 94158

Page 70 of 77

DSMC Monitors Box 0128 UCSF HDFCCC San Francisco, CA 94143

Page 71 of 77

Appendix K.8 (Multicenter) Data and Safety Monitoring Plan for a Multicenter Study (Phase II or III study)

1. Oversight and Monitoring Plan

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and patient safety for all HDF CCC institutional clinical studies. A summary of DSMC activities for this study includes:

- Review of patient data.
- Review of serious adverse events.
- Monitoring every six months (depending on patient accrual).
- Minimum of a yearly regulatory audit.

2. Monitoring and Reporting Guidelines

All institutional Phase II or III therapeutic studies are designated with a moderate risk assessment (see Appendix H). The data is monitored by a DSMC Monitor twice per year with twenty percent of the patients monitored (or at least three patients if the calculated value is less than three).

The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites to communicate the review of adverse events, safety data, and other study matters.

The Principal Investigator at the UCSF Coordinating Center will hold the role of Study Chair. The Study Chair is responsible for the overall conduct of the study and for monitoring its safety and progress at all participating sites. The Study Chair will conduct continuous review of data and patient safety and discuss each patient's treatment at monthly UCSF Site Committee meetings. The discussions are documented in the UCSF Site Committee meeting minutes.

Multicenter communication

The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites. The following issues will be discussed as appropriate:

Page 72 of 77

- Enrollment information.
- Adverse Events (i.e., new adverse events and updates on unresolved adverse events and new safety information).
- Protocol Violations.
- Other issues affecting the conduct of the study.

Adverse events reporting to the DSMC will include reports from both the UCSF Coordinating Center, as well as the participating sites. The DSMC will be responsible for monitoring all data entered in OnCore® at the UCSF Coordinating Center and the participating sites as per the study-specific guidelines listed in Appendix H. The data (i.e., copies of source documents) from the participating sites will be downloaded into the PC console of OnCore prior to the monitoring visits in order for the DSMC to monitor the participating site's compliance with the protocol and FDA regulations.

3 Review and Oversight Requirements

3.1 Adverse Event Monitoring

All Grade 3-5 Adverse Events (AEs), regardless of being unexpected or considered to be associated with the use of the study drug will be entered into OnCore®, UCSF's Clinical Trial Management System.

Adverse Events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse Events are further given an assignment of attribution or relationship to treatment or medical procedure. Attribution categories are:

- **Definite** The adverse event is clearly related to the investigational agent(s) or medical procedure.
- **Probable** The adverse event is likely related to the investigational agent(s) or medical procedure.
- **Possible** The adverse event may be related to the investigational agent(s) or medical procedure.
- **Unlikely** The adverse event is doubtfully related to the investigational agent(s) or medical procedure.
- **Unrelated** the adverse event is clearly not related to the investigational agent(s) or medical procedure.

Page 73 of 77

All Grade 3-5 adverse events entered into OnCore® will be reviewed on a monthly basis at the UCSF Site Committee meetings. All adverse events entered into OnCore® will be reviewed on a monthly basis at the UCSF Coordinating Center Site Committee meetings. All clinically significant adverse events must be reported to the UCSF Coordinating Center by the participating sites within 10 business days of becoming aware of the event or during the next scheduled monthly conference call, whichever is sooner. The UCSF Site Committee will review and discuss the selected toxicity, the toxicity grade, and the attribution of relationship of the adverse event to the administration of the study drug(s) from the UCSF Coordinating Center and the participating sites.

3.2 Serious Adverse Event Reporting

By definition, an Adverse Event is defined as a Serious Adverse Event (SAE) according to the following criteria:

- Death.
- Life-threatening (i.e. results in an immediate risk of death).
- Requires inpatient hospitalization or prolongation of existing hospitalization.
- Permanent or significant disability/incapacity.
- Gives rise to a congenital anomaly/birth defect, or cancer, or any experience that suggests a significant hazard, contraindication, side effect, or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above.
- Event occurring in a gene therapy study.
- Event that changes the risk/benefit ratio of a study.
- Any other event the Principal Investigator judges to be serious or which would suggest a significant hazard, contraindication, side effect, or precaution.

Serious Adverse Event reporting will be in accordance with the UCSF IRB Regulations and Code of Federal Regulation Title 21 Part 312.32. The SAE will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events:

https://irb.ucsf.edu/adverse-event

FDA website for guidance in reporting serious adverse events:

www.fda.gov/Safety/MedWatch/HowToReport/default.htm

Page 74 of 77

Med Watch forms and information:

www.fda.gov/medwatch/getforms.htm

All Serious Adverse Events are entered into OnCore®, as well as submitted to the IRB (per IRB guidelines) via iRIS®. All SAEs, whether expected or unexpected, must be reported to the UCSF Coordinating Center within 1 business days of becoming aware of the event. The SAEs are reviewed and monitored by the UCSF Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every six weeks. The date the SAE was sent to all required reporting agencies will be documented in OnCore®.

If a death occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s) and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Study Chair at the UCSF Coordinating Center or the assigned designee must be notified within 1 business day from the participating site(s) and the Study Chair must then notify the DSMC Chair or qualified alternate within 1 business day of this notification. The reporting procedure is by communication via phone or in person with written documentation of the one-on-one communication via e-mail, with a copy of the e- mail to the DSMC Manager.

3.3 Review of Adverse Event Rates

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Study Chair at the UCSF Coordinating Center is responsible for notifying the DSMC at the time the increased rate is identified. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the Study Chair stops enrollment or stops the study due to safety issues, the DSMC Chair and DSMC Manager must be notified within 1 business day and the IRB must be notified within 10 business days via an iRIS Reporting Form.

Data and Safety Monitoring Committee Contacts:

Page 75 of 77

Thierry Jahan, MD 415-885-3792 Thierry.jahan@ucsf.edu Box 1705 UCSF HDFCCC San Francisco, CA 94158

DSMC Monitors Box 0128 UCSF HDFCCC San Francisco, CA 94143

Page 76 of 77

Appendix L. Risk Assessment for Institutional Studies:

Risk	Study type	Monitoring	Surveillance
assignment			
High	Institutional Phase 1 therapeutic	Monitor all study patients in real-time as enrolled/ monitor through DLT period	Real time monitoring of AEs and SAE's weekly at site committees; DSMC monitors SAE every six weeks at DSMC Meetings
High	All Institutional therapeutic using gene therapy or vaccines, regardless of phase	Monitor all patients as enrolled/ monitor first three treatments/cycles	Real time monitoring of AEs and SAEs weekly at site committees; DSMC monitors SAE every six weeks at DSMC Meetings
Moderate	Institutional Phase II therapeutic	Audit all data in 20% of study patients twice per year	Real time monitoring of AEs and SAEs monthly at site committees; DSMC monitors SAE every six weeks at DSMC Meetings
Moderate	Institutional Phase III therapeutic	Audit all data in 20% of study patients enrolled in trial twice per year	Real time monitoring of AEs and SAEs monthly at site committees; DSMC monitors SAE every six weeks at DSMC Meetings
Low	Non-therapeutic trials	Audit all data in 20% of study patients enrolled in trial once per/year	DSMC monitors for SAEs every six weeks at DSMC Meetings

The table below lists the risk assessment for the institutional studies monitored by the DSMC:

Page 77 of 77